Relationship	O
between	O
IkappaBalpha	B-protein
constitutive	O
expression	O
,	O
TNFalpha	B-protein
synthesis	O
,	O
and	O
apoptosis	O
in	O
EBV-infected	B-cell_type
lymphoblastoid	I-cell_type
cells	I-cell_type
.	O

In	O
order	O
to	O
understand	O
the	O
role	O
of	O
NF-kappaB	B-protein
in	O
EBV	O
transformation	O
we	O
have	O
established	O
stably	O
transfected	O
IkappaBalpha	B-protein
into	O
lymphoblastoid	B-cell_type
cells	I-cell_type
.	O

Two	O
clones	O
were	O
obtained	O
in	O
which	O
the	O
loss	O
of	O
NF-kappaB	B-protein
binding	O
activity	O
correlated	O
with	O
the	O
constitutive	O
expression	O
of	O
the	O
transgenic	O
IkappaBalpha	B-protein
.	O

Protein	O
latency	O
expression	O
was	O
determined	O
by	O
immunocytochemistry	O
.	O

Expression	O
of	O
surface	O
markers	O
,	O
intracytoplasmic	O
content	O
of	O
cytokines	B-protein
cell	O
cycle	O
analysis	O
after	O
BrdU	B-protein
incorporation	O
and	O
DNA	O
staining	O
with	O
propidium	O
iodide	O
were	O
studied	O
by	O
flow	O
cytometry	O
.	O

Percentage	O
of	O
apoptotic	B-cell_type
cells	I-cell_type
was	O
determined	O
by	O
in-situ	O
labelling	O
of	O
DNA	O
strand	O
breaks	O
.	O

No	O
significative	O
changes	O
in	O
EBV	O
latency	O
nor	O
in	O
cell	O
surface	O
marker	O
expression	O
was	O
found	O
.	O

In	O
contrast	O
,	O
intracytoplasmic	O
TNFalpha	B-protein
levels	O
were	O
strongly	O
reduced	O
in	O
transfected	B-cell_line
clones	I-cell_line
.	O

Furthermore	O
,	O
30	O
%	O
of	O
IkappaBalpha	B-cell_line
transfected	I-cell_line
cells	I-cell_line
were	O
apoptotic	O
after	O
8	O
h	O
of	O
TNFalpha	B-protein
treatment	O
.	O

This	O
correlated	O
with	O
a	O
strong	O
reduction	O
of	O
BrdU	O
incorporation	O
after	O
24	O
h	O
of	O
TNFalpha	B-protein
treatment	O
.	O

No	O
effect	O
was	O
seen	O
with	O
non	O
transfected	B-cell_line
cells	I-cell_line
or	O
with	O
cells	O
transfected	O
with	O
a	O
control	O
plasmid	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
TNFalpha	B-DNA
gene	I-DNA
could	O
be	O
one	O
of	O
the	O
targets	O
of	O
NF-kappaB	B-protein
in	O
EBV	O
infected	O
cells	O
and	O
that	O
NF-kappaB	B-cell_type
protects	I-cell_type
EBV-infected	I-cell_type
cells	I-cell_type
from	O
apoptosis	O
induced	O
by	O
TNFalpha	B-protein
,	O
which	O
may	O
favour	O
the	O
proliferative	O
effect	O
of	O
this	O
cytokine	B-protein
.	O

Oncogene	NULL
(	NULL
1998	NULL
)	NULL
17	NULL
,	NULL
1607-1615	NULL
©	NULL
1998	NULL
Stockton	NULL
Press	NULL
All	NULL
rights	NULL
reserved	NULL
0950-9232/98	NULL
$	NULL
12.00	NULL
http	NULL
:	NULL
//www	NULL
.	NULL

stockton-press.co.uk/onc	NULL
Relationship	NULL
between	NULL
IxB	NULL
&	NULL
constitutive	NULL
expression	NULL
,	NULL
TNFa	NULL
synthesis	NULL
,	NULL
and	NULL
apoptosis	NULL
in	NULL
EBV-infected	NULL
lymphoblastoid	NULL
cells	NULL
Marianne	NULL
Asso-Bonnet	NULL
'	NULL
,	NULL
Jean	NULL
Feuillard	NULL
'	NULL
,	NULL
Valérie	NULL
Ferreira	NULL
``	NULL
,	NULL
Philippe	NULL
Bissigres	NULL
'	NULL
,	NULL
Nadine	NULL
Tarantino	NULL
,	NULL
Marie	NULL
Korner	NULL
and	NULL
Martine	NULL
Raphael	NULL
!	NULL

'Service	NULL
d'Hématologie	NULL
Biologique	NULL
,	NULL
Hopital	NULL
Avicenne	NULL
;	NULL
and	NULL
URA	NULL
625	NULL
,	NULL
Hopital	NULL
Pitié-Salpétriére	NULL
,	NULL
France	NULL
In	NULL
order	NULL
to	NULL
understand	NULL
the	NULL
role	NULL
of	NULL
NF-xB	NULL
in	NULL
EBV	NULL
transformation	NULL
we	NULL
have	NULL
established	NULL
stably	NULL
transfected	NULL
IxBx	NULL
into	NULL
lymphoblastoid	NULL
cells	NULL
.	NULL

Two	NULL
clones	NULL
were	NULL
obtained	NULL
in	NULL
which	NULL
the	NULL
loss	NULL
of	NULL
NF-xB	NULL
binding	NULL
activity	NULL
correlated	NULL
with	NULL
the	NULL
constitutive	NULL
expression	NULL
of	NULL
the	NULL
transgenic	NULL
Protein	NULL
latency	NULL
expression	NULL
was	NULL
determined	NULL
by	NULL
immunocytochemistry	NULL
.	NULL

Expression	NULL
of	NULL
surface	NULL
markers	NULL
,	NULL
intracytoplasmic	NULL
content	NULL
of	NULL
cytokines	NULL
cell	NULL
cycle	NULL
analysis	NULL
after	NULL
BrdU	NULL
incorporation	NULL
and	NULL
DNA	NULL
staining	NULL
with	NULL
propidium	NULL
iodide	NULL
were	NULL
studied	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Percentage	NULL
of	NULL
apoptotic	NULL
cells	NULL
was	NULL
determined	NULL
by	NULL
in-situ	NULL
labelling	NULL
of	NULL
DNA	NULL
strand	NULL
breaks	NULL
.	NULL

No	NULL
significative	NULL
changes	NULL
in	NULL
EBV	NULL
latency	NULL
nor	NULL
in	NULL
cell	NULL
surface	NULL
marker	NULL
expression	NULL
was	NULL
found	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
intracytoplasmic	NULL
TNFx	NULL
levels	NULL
were	NULL
strongly	NULL
reduced	NULL
in	NULL
transfected	NULL
clones	NULL
.	NULL

Furthermore	NULL
,	NULL
30	NULL
%	NULL
of	NULL
IxBa	NULL
transfected	NULL
cells	NULL
were	NULL
apoptotic	NULL
after	NULL
8	NULL
h	NULL
of	NULL
TNF	NULL
«	NULL
treatment	NULL
.	NULL

This	NULL
correlated	NULL
with	NULL
a	NULL
strong	NULL
reduction	NULL
of	NULL
BrdU	NULL
incorporation	NULL
after	NULL
24	NULL
h	NULL
of	NULL
TNF	NULL
treatment	NULL
.	NULL

No	NULL
effect	NULL
was	NULL
seen	NULL
with	NULL
non	NULL
transfected	NULL
cells	NULL
or	NULL
with	NULL
cells	NULL
transfected	NULL
with	NULL
a	NULL
control	NULL
plasmid	NULL
.	NULL

Our	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
TNFx	NULL
gene	NULL
could	NULL
be	NULL
one	NULL
of	NULL
the	NULL
targets	NULL
of	NULL
NF-xB	NULL
in	NULL
EBV	NULL
infected	NULL
cells	NULL
and	NULL
that	NULL
NF-xB	NULL
protects	NULL
EBV-infected	NULL
cells	NULL
from	NULL
apoptosis	NULL
induced	NULL
by	NULL
TNF	NULL
&	NULL
,	NULL
which	NULL
may	NULL
favour	NULL
the	NULL
proliferative	NULL
effect	NULL
of	NULL
this	NULL
cytokine	NULL
.	NULL

Keywords	NULL
:	NULL
NF-xB	NULL
;	NULL
IxB	NULL
&	NULL
;	NULL
EBV	NULL
;	NULL
TNFa	NULL
Introduction	NULL
The	NULL
Epstein	NULL
Barr	NULL
Virus	NULL
(	NULL
EBV	NULL
)	NULL
is	NULL
able	NULL
to	NULL
infect	NULL
and	NULL
transform	NULL
non	NULL
tumoral	NULL
B-cells	NULL
in	NULL
vitro	NULL
and	NULL
is	NULL
associated	NULL
with	NULL
several	NULL
human	NULL
malignancies	NULL
,	NULL
such	NULL
as	NULL
lymphopro-liferative	NULL
diseases	NULL
in	NULL
immunocompromised	NULL
patients	NULL
,	NULL
endemic	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
or	NULL
Hodgkin	NULL
's	NULL
disease	NULL
(	NULL
see	NULL
Kieff	NULL
and	NULL
Liecbowtz	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
EBV-transformation	NULL
of	NULL
B-cells	NULL
is	NULL
associated	NULL
with	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
restricted	NULL
set	NULL
of	NULL
proteins	NULL
,	NULL
so-called	NULL
latency	NULL
proteins	NULL
.	NULL

Among	NULL
them	NULL
,	NULL
the	NULL
LMPI1	NULL
protein	NULL
has	NULL
been	NULL
extensively	NULL
studied	NULL
.	NULL

After	NULL
transfection	NULL
,	NULL
this	NULL
membrane	NULL
protein	NULL
is	NULL
able	NULL
to	NULL
transform	NULL
cells	NULL
,	NULL
as	NULL
well	NULL
as	NULL
to	NULL
confer	NULL
the	NULL
activated	NULL
phenotype	NULL
of	NULL
EBV-infected	NULL
cells	NULL
.	NULL

Results	NULL
from	NULL
several	NULL
groups	NULL
demonstrated	NULL
that	NULL
LMP1	NULL
protein	NULL
interacts	NULL
directly	NULL
with	NULL
TRAF	NULL
molecules	NULL
(	NULL
Mosialos	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
,	NULL
which	NULL
aggregation	NULL
is	NULL
an	NULL
essential	NULL
step	NULL
in	NULL
the	NULL
transduction	NULL
pathway	NULL
of	NULL
various	NULL
member	NULL
of	NULL
the	NULL
TNFa	NULL
«	NULL
receptor	NULL
family	NULL
such	NULL
as	NULL
TNFa	NULL
Correspondence	NULL
:	NULL
J	NULL
Feuillard	NULL
,	NULL
Service	NULL
d'Hématologie	NULL
Biologique	NULL
,	NULL
Hopital	NULL
Avicenne	NULL
,	NULL
Bobigny	NULL
,	NULL
France	NULL
Received	NULL
3	NULL
March	NULL
1998	NULL
;	NULL
revised	NULL
17	NULL
August	NULL
1998	NULL
;	NULL
accepted	NULL
17	NULL
August	NULL
1998	NULL
receptor	NULL
types	NULL
I	NULL
and	NULL
II	NULL
,	NULL
CD30	NULL
,	NULL
CD40	NULL
.	NULL

LMPI	NULL
protein	NULL
induces	NULL
multiple	NULL
downstream	NULL
effects	NULL
,	NULL
among	NULL
which	NULL
cell	NULL
proliferation	NULL
and	NULL
activation	NULL
of	NULL
Rel/NF-xB	NULL
proteins	NULL
(	NULL
Laherty	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

The	NULL
Rel/NF-xB	NULL
proteins	NULL
constitute	NULL
a	NULL
family	NULL
of	NULL
ubiquitously	NULL
expressed	NULL
eukaryotic	NULL
factors	NULL
that	NULL
comprises	NULL
p50	NULL
,	NULL
p52	NULL
,	NULL
p65	NULL
,	NULL
c-Rel	NULL
and	NULL
RelB	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

The	NULL
members	NULL
of	NULL
this	NULL
family	NULL
are	NULL
defined	NULL
as	NULL
sharing	NULL
the	NULL
Rel	NULL
homology	NULL
domain	NULL
,	NULL
a	NULL
conserved	NULL
region	NULL
of	NULL
approximately	NULL
300	NULL
amino	NULL
acids	NULL
that	NULL
contains	NULL
critical	NULL
sequences	NULL
for	NULL
dimerization	NULL
,	NULL
DNA-binding	NULL
and	NULL
nuclear	NULL
localization	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
these	NULL
proteins	NULL
is	NULL
related	NULL
to	NULL
the	NULL
formation	NULL
of	NULL
homo	NULL
or	NULL
heterodimers	NULL
with	NULL
one	NULL
of	NULL
the	NULL
other	NULL
members	NULL
of	NULL
the	NULL
family	NULL
.	NULL

These	NULL
proteins	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
positive	NULL
control	NULL
of	NULL
the	NULL
transcription	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
genes	NULL
involved	NULL
in	NULL
the	NULL
immune	NULL
response	NULL
(	NULL
TNFa	NULL
«	NULL
,	NULL
interleukin	NULL
1	NULL
,	NULL
MHC	NULL
class	NULL
II	NULL
,	NULL
some	NULL
adhesion	NULL
molecules	NULL
such	NULL
as	NULL
ICAMI	NULL
...	NULL
)	NULL
,	NULL
the	NULL
inflammatory	NULL
response	NULL
(	NULL
i-NO	NULL
synthase	NULL
,	NULL
interleukin	NULL
6	NULL
...	NULL
)	NULL
or	NULL
onco-genes	NULL
such	NULL
as	NULL
c-myc	NULL
as	NULL
well	NULL
as	NULL
some	NULL
viruses	NULL
such	NULL
as	NULL
HIV1	NULL
,	NULL
CMV	NULL
,	NULL
SV40	NULL
(	NULL
see	NULL
Baeuerle	NULL
and	NULL
Henkel	NULL
,	NULL
1994	NULL
;	NULL
Grilli	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
for	NULL
review	NULL
)	NULL
.	NULL

The	NULL
cytoplasmic	NULL
localization	NULL
of	NULL
these	NULL
proteins	NULL
is	NULL
due	NULL
to	NULL
the	NULL
masking	NULL
of	NULL
the	NULL
nuclear	NULL
localization	NULL
sequence	NULL
by	NULL
interaction	NULL
with	NULL
one	NULL
of	NULL
the	NULL
IxB	NULL
family	NULL
inhibitors	NULL
:	NULL
IxBa	NULL
«	NULL
,	NULL
B	NULL
,	NULL
y	NULL
,	NULL
6	NULL
and	NULL
s	NULL
(	NULL
Verma	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
for	NULL
review	NULL
)	NULL
.	NULL

Following	NULL
various	NULL
cell	NULL
activation	NULL
events	NULL
,	NULL
such	NULL
as	NULL
B-cell	NULL
receptor	NULL
or	NULL
T-cell	NULL
receptor	NULL
stimulation	NULL
,	NULL
exposure	NULL
to	NULL
certain	NULL
cytokines	NULL
or	NULL
some	NULL
viral	NULL
infections	NULL
,	NULL
Rel/NF-xB	NULL
dimers	NULL
are	NULL
activated	NULL
.	NULL

This	NULL
activation	NULL
corresponds	NULL
to	NULL
their	NULL
nuclear	NULL
translocation	NULL
after	NULL
serine	NULL
phosphorylation	NULL
and	NULL
proteolytic	NULL
degradation	NULL
of	NULL
IxB	NULL
.	NULL

In	NULL
the	NULL
nucleus	NULL
,	NULL
Rel/NF-xB	NULL
heterodimers	NULL
are	NULL
thought	NULL
to	NULL
enhance	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
a	NULL
defined	NULL
set	NULL
of	NULL
genes	NULL
through	NULL
their	NULL
binding	NULL
to	NULL
a	NULL
(	NULL
xB	NULL
site	NULL
'	NULL
,	NULL
a	NULL
specific	NULL
DNA-sequence	NULL
containing	NULL
the	NULL
consensus	NULL
sequence	NULL
GGGRNNYYCC	NULL
.	NULL

The	NULL
involvement	NULL
of	NULL
Rel/NF-xB	NULL
dysregulation	NULL
in	NULL
tumorigenesis	NULL
has	NULL
been	NULL
suggested	NULL
by	NULL
various	NULL
reports	NULL
in	NULL
the	NULL
literature	NULL
.	NULL

For	NULL
example	NULL
,	NULL
the	NULL
viral	NULL
equivalent	NULL
of	NULL
c-Rel	NULL
,	NULL
v-Rel	NULL
,	NULL
which	NULL
correspond	NULL
to	NULL
a	NULL
truncated	NULL
and	NULL
mutated	NULL
version	NULL
of	NULL
c-Rel	NULL
,	NULL
is	NULL
responsible	NULL
for	NULL
fatal	NULL
haematological	NULL
diseases	NULL
in	NULL
chicken	NULL
and	NULL
turkey	NULL
,	NULL
and	NULL
transgenic	NULL
mice	NULL
expressing	NULL
v-Rel	NULL
present	NULL
rapid	NULL
T-cell	NULL
lymphoblastic	NULL
disorders	NULL
(	NULL
Carrasco	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Simek	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Stephens	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1983	NULL
)	NULL
.	NULL

One	NULL
of	NULL
the	NULL
first	NULL
reports	NULL
which	NULL
describes	NULL
the	NULL
cloning	NULL
of	NULL
p52	NULL
correspond	NULL
to	NULL
the	NULL
description	NULL
of	NULL
the	NULL
Lyt-10	NULL
protein	NULL
,	NULL
which	NULL
locus	NULL
is	NULL
rearranged	NULL
with	NULL
the	NULL
t	NULL
(	NULL
10:14	NULL
)	NULL
chromosomic	NULL
translocation	NULL
(	NULL
Neri	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

This	NULL
translocation	NULL
has	NULL
been	NULL
reported	NULL
in	NULL
14	NULL
%	NULL
of	NULL
the	NULL
Sezary	NULL
T-Cell	NULL
lymphoma	NULL
(	NULL
Migliazza	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Aberrant	NULL
Rel/NF-xB	NULL
protein	NULL
expression	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
associated	NULL
with	NULL
the	NULL
malignant	NULL
progression	NULL
in	NULL
breast	NULL
cancers	NULL
(	NULL
Nakshatri	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
;	NULL
Sovak	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Amplification	NULL
of	NULL
the	NULL
Rel	NULL
Roles	NULL
of	NULL
NF-xB	NULL
activation	NULL
in	NULL
EBV-infected	NULL
B-lymphocytes	NULL
M	NULL
Asso-Bonnet	NULL
et	NULL
al	NULL
1608	NULL
locus	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
a	NULL
feature	NULL
of	NULL
primary	NULL
extranodal	NULL
lymphoma	NULL
(	NULL
Houldsworth	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Antisense	NULL
oligonucleotides	NULL
raised	NULL
against	NULL
the	NULL
p65	NULL
mRNA	NULL
inhibit	NULL
the	NULL
proliferation	NULL
of	NULL
tumoral	NULL
cells	NULL
whereas	NULL
sense	NULL
oligonucleotides	NULL
favour	NULL
proliferation	NULL
of	NULL
tumoral	NULL
cells	NULL
(	NULL
Higgins	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
LMPI1	NULL
,	NULL
the	NULL
major	NULL
transforming	NULL
EBV	NULL
latency	NULL
protein	NULL
,	NULL
is	NULL
responsible	NULL
for	NULL
NF-xB	NULL
activation	NULL
in	NULL
EBV	NULL
infected	NULL
B-cells	NULL
strongly	NULL
suggests	NULL
that	NULL
Rel/NF-xB	NULL
complexes	NULL
could	NULL
play	NULL
a	NULL
role	NULL
in	NULL
EBV-related	NULL
lymphomagenesis	NULL
.	NULL

The	NULL
NF-xB	NULL
activation	NULL
domain	NULL
of	NULL
LMPI1	NULL
has	NULL
been	NULL
well	NULL
defined	NULL
,	NULL
and	NULL
in	NULL
vitro	NULL
mutations	NULL
or	NULL
deletions	NULL
within	NULL
this	NULL
domain	NULL
are	NULL
associated	NULL
with	NULL
the	NULL
loss	NULL
of	NULL
NF-kB	NULL
activation	NULL
(	NULL
Huen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

However	NULL
,	NULL
natural	NULL
variants	NULL
of	NULL
LMPI	NULL
from	NULL
EBV	NULL
isolates	NULL
still	NULL
have	NULL
the	NULL
capacity	NULL
to	NULL
activate	NULL
NF-xB	NULL
,	NULL
even	NULL
if	NULL
mutations	NULL
or	NULL
deletions	NULL
are	NULL
occurring	NULL
within	NULL
the	NULL
NF-xB	NULL
activation	NULL
domain	NULL
,	NULL
suggesting	NULL
that	NULL
it	NULL
exerts	NULL
a	NULL
selective	NULL
pressure	NULL
on	NULL
EBV	NULL
strains	NULL
to	NULL
keep	NULL
intact	NULL
the	NULL
capacity	NULL
of	NULL
NF-xB	NULL
activation	NULL
through	NULL
the	NULL
LMP1I	NULL
proteins	NULL
in	NULL
EBV-infected	NULL
B-cells	NULL
(	NULL
Rothenberger	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

LMPI	NULL
activation	NULL
of	NULL
NF-xB	NULL
corresponds	NULL
to	NULL
the	NULL
translocation	NULL
of	NULL
p65/p50	NULL
complexes	NULL
in	NULL
the	NULL
nucleus	NULL
,	NULL
and	NULL
targets	NULL
IxBa	NULL
«	NULL
phosphorylation	NULL
and	NULL
degradation	NULL
,	NULL
and	NULL
over-expression	NULL
of	NULL
IxBa	NULL
«	NULL
inhibits	NULL
the	NULL
NF-xB	NULL
activation	NULL
by	NULL
LMPI1	NULL
(	NULL
Herrero	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
IxBa	NULL
«	NULL
expressing	NULL
vectors	NULL
could	NULL
be	NULL
an	NULL
interesting	NULL
tool	NULL
in	NULL
controlling	NULL
NF-xB	NULL
activity	NULL
and	NULL
thus	NULL
,	NULL
to	NULL
understand	NULL
the	NULL
relationships	NULL
between	NULL
EBV-induced	NULL
transformation	NULL
and	NULL
NF-xB	NULL
activation	NULL
.	NULL

In	NULL
order	NULL
to	NULL
understand	NULL
the	NULL
role	NULL
of	NULL
Rel/NF-xB	NULL
proteins	NULL
in	NULL
EBV-related	NULL
lymphomagenesis	NULL
,	NULL
we	NULL
have	NULL
stably	NULL
transfected	NULL
the	NULL
IxB	NULL
«	NULL
cDNA	NULL
,	NULL
mutated	NULL
on	NULL
serine	NULL
32	NULL
and	NULL
36	NULL
,	NULL
which	NULL
blocks	NULL
its	NULL
degradation	NULL
in	NULL
a	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
(	NULL
LCL	NULL
)	NULL
.	NULL

This	NULL
mutated	NULL
IxBa	NULL
is	NULL
no	NULL
longer	NULL
degraded	NULL
in	NULL
response	NULL
to	NULL
activating	NULL
signals	NULL
.	NULL

We	NULL
have	NULL
obtained	NULL
two	NULL
clones	NULL
in	NULL
which	NULL
expression	NULL
of	NULL
the	NULL
transgene	NULL
was	NULL
correlated	NULL
with	NULL
the	NULL
loss	NULL
of	NULL
NF-xB	NULL
binding	NULL
activity	NULL
.	NULL

We	NULL
have	NULL
analysed	NULL
the	NULL
EBV	NULL
latency	NULL
,	NULL
surface	NULL
phenotype	NULL
,	NULL
intracytoplasmic	NULL
cytokine	NULL
content	NULL
,	NULL
cellular	NULL
proliferation	NULL
and	NULL
apoptosis	NULL
.	NULL

We	NULL
show	NULL
that	NULL
intracytoplasmic	NULL
levels	NULL
of	NULL
TNFa	NULL
in	NULL
IxBa	NULL
«	NULL
transfected	NULL
clones	NULL
were	NULL
reduced	NULL
to	NULL
the	NULL
level	NULL
of	NULL
EBV	NULL
negative	NULL
B	NULL
cell	NULL
lines	NULL
.	NULL

Moreover	NULL
,	NULL
TNF	NULL
«	NULL
induced	NULL
both	NULL
cell	NULL
apoptosis	NULL
and	NULL
cell	NULL
proliferation	NULL
arrest	NULL
in	NULL
IxBa	NULL
«	NULL
transfected	NULL
cell	NULL
.	NULL

Results	NULL
Establishment	NULL
of	NULL
stably	NULL
transfected	NULL
lymphoblastoid	NULL
cells	NULL
with	NULL
the	NULL
mutated	NULL
IxBx	NULL
cDNA	NULL
In	NULL
agreement	NULL
with	NULL
previous	NULL
reports	NULL
,	NULL
preliminary	NULL
experiments	NULL
showed	NULL
that	NULL
all	NULL
EBV	NULL
positive	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
had	NULL
a	NULL
constitutive	NULL
NF-xB	NULL
binding	NULL
activity	NULL
.	NULL

This	NULL
NF-xB	NULL
was	NULL
not	NULL
enhanced	NULL
after	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
,	NULL
although	NULL
this	NULL
treatment	NULL
was	NULL
efficient	NULL
on	NULL
NF-xB	NULL
induction	NULL
in	NULL
EBV	NULL
(	NULL
-	NULL
)	NULL
Burkitt	NULL
cell	NULL
lines	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Supershift	NULL
experiments	NULL
showed	NULL
the	NULL
presence	NULL
of	NULL
p65/p50	NULL
and	NULL
p50	NULL
,	NULL
complexes	NULL
(	NULL
Figure	NULL
la	NULL
)	NULL
.	NULL

We	NULL
have	NULL
transfected	NULL
the	NULL
pcDNA3	NULL
vector	NULL
containing	NULL
the	NULL
mutated	NULL
cDNA	NULL
of	NULL
IxBa	NULL
under	NULL
the	NULL
control	NULL
of	NULL
CMV	NULL
promoter	NULL
,	NULL
into	NULL
lymphoblastoid	NULL
cells	NULL
.	NULL

Mutations	NULL
consist	NULL
in	NULL
substitution	NULL
of	NULL
the	NULL
two	NULL
serine	NULL
32	NULL
and	NULL
36	NULL
by	NULL
alanines	NULL
(	NULL
IxBo	NULL
;	NULL
;	NULL
,	NULL
a	NULL
)	NULL
(	NULL
Traenckner	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Control	NULL
transfection	NULL
experiments	NULL
were	NULL
performed	NULL
in	NULL
parallel	NULL
with	NULL
the	NULL
empty	NULL
plasmid	NULL
.	NULL

Thirty-five	NULL
clones	NULL
out	NULL
of	NULL
576	NULL
ensemenced	NULL
p32/p30	NULL
p30/p50	NULL
_	NULL
,	NULL
.	NULL

Mut	NULL
IxBa	NULL
--	NULL
IxBax	NULL
Figure	NULL
1	NULL
.	NULL

Characterization	NULL
of	NULL
IxBx	NULL
transfected	NULL
cells	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Gel	NULL
retardation	NULL
of	NULL
°°P-xB	NULL
probe	NULL
with	NULL
the	NULL
non	NULL
transfected	NULL
LCL	NULL
PRI	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
and	NULL
supershift	NULL
experiments	NULL
with	NULL
anti-p50	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
anti-p635	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
,	NULL
anti-c-Rel	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
anti-p52	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
and	NULL
anti-RelB	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
immune	NULL
serum	NULL
.	NULL

Immune	NULL
serum	NULL
against	NULL
p65	NULL
were	NULL
raised	NULL
against	NULL
the	NULL
N	NULL
terminus	NULL
of	NULL
p65	NULL
(	NULL
lane	NULL
3	NULL
,	NULL
immune	NULL
serum	NULL
no	NULL
1207	NULL
)	NULL
or	NULL
the	NULL
C-terminus	NULL
of	NULL
p65	NULL
(	NULL
lane	NULL
4	NULL
,	NULL
immune	NULL
serum	NULL
no	NULL
1226	NULL
)	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Gel	NULL
retardation	NULL
of	NULL
°°P-xB	NULL
probe	NULL
with	NULL
the	NULL
non	NULL
transfected	NULL
LCL	NULL
PRI	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
the	NULL
clone	NULL
12F8	NULL
transfected	NULL
with	NULL
the	NULL
control	NULL
plasmid	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
and	NULL
IxBa	NULL
«	NULL
transfected	NULL
clones	NULL
9B8	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
9C4	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
and	NULL
X9	NULL
(	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
,	NULL
in	NULL
absence	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
7	NULL
and	NULL
9	NULL
)	NULL
or	NULL
in	NULL
presence	NULL
of	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
8	NULL
and	NULL
10	NULL
)	NULL
.	NULL

(	NULL
c	NULL
)	NULL
Western	NULL
blot	NULL
detection	NULL
of	NULL
mutated	NULL
IxBaz	NULL
>	NULL
/sea	NULL
;	NULL
lane	NULL
1	NULL
:	NULL
non	NULL
transfected	NULL
LCL	NULL
cells	NULL
;	NULL
lane	NULL
2	NULL
:	NULL
9B8	NULL
IxBaz	NULL
»	NULL
/34a	NULL
transfected	NULL
clone	NULL
;	NULL
lane	NULL
3	NULL
:	NULL
X9	NULL
transfected	NULL
clone	NULL
;	NULL
lane	NULL
4	NULL
:	NULL
12F8	NULL
clone	NULL
transfected	NULL
with	NULL
the	NULL
control	NULL
plasmid	NULL
;	NULL
lane	NULL
5	NULL
:	NULL
HPB-ALL	NULL
IxBa37/36a	NULL
transfected	NULL
clone	NULL
wells	NULL
were	NULL
growing	NULL
in	NULL
selective	NULL
medium	NULL
.	NULL

Clones	NULL
were	NULL
screened	NULL
for	NULL
both	NULL
the	NULL
loss	NULL
of	NULL
NF-xB	NULL
binding	NULL
activity	NULL
by	NULL
EMSA	NULL
and	NULL
genomic	NULL
integration	NULL
of	NULL
cDNA	NULL
by	NULL
Southern	NULL
blot	NULL
.	NULL

Three	NULL
clones	NULL
9C4	NULL
,	NULL
9B8	NULL
and	NULL
X9	NULL
showed	NULL
a	NULL
genomic	NULL
integration	NULL
of	NULL
cDNA	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Among	NULL
them	NULL
,	NULL
the	NULL
9C4	NULL
clone	NULL
still	NULL
had	NULL
constitutive	NULL
nuclear	NULL
NF-xB	NULL
binding	NULL
activity	NULL
(	NULL
see	NULL
Figure	NULL
1b	NULL
)	NULL
.	NULL

Constitutive	NULL
NF-xB	NULL
binding	NULL
activity	NULL
was	NULL
almost	NULL
abolished	NULL
in	NULL
9B8	NULL
clone	NULL
and	NULL
totally	NULL
abolished	NULL
in	NULL
X9	NULL
clone	NULL
(	NULL
Figure	NULL
1b	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
cells	NULL
with	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
failed	NULL
to	NULL
induce	NULL
a	NULL
nuclear	NULL
NF-xB	NULL
binding	NULL
activity	NULL
in	NULL
X9	NULL
clone	NULL
and	NULL
induced	NULL
a	NULL
hardly	NULL
visible	NULL
signal	NULL
in	NULL
9B8	NULL
clone	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
IxBx	NULL
;	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
protein	NULL
was	NULL
done	NULL
by	NULL
Western	NULL
blot	NULL
.	NULL

The	NULL
wild	NULL
type	NULL
and	NULL
the	NULL
are	NULL
distinguishable	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
their	NULL
electrophoretic	NULL
migration	NULL
because	NULL
the	NULL
IxBa	NULL
;	NULL
;	NULL
,	NULL
;	NULL
,	NULL
,	NULL
migrates	NULL
slightly	NULL
slower	NULL
in	NULL
SDS	NULL
gels	NULL
(	NULL
Traenckner	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Control	NULL
experiments	NULL
indicating	NULL
the	NULL
position	NULL
of	NULL
the	NULL
IxBOz	NULL
,	NULL
protein	NULL
were	NULL
done	NULL
using	NULL
a	NULL
clone	NULL
previously	NULL
described	NULL
by	NULL
HPB-ALL	NULL
T-lymphoblast	NULL
cell	NULL
line	NULL
stably	NULL
transfected	NULL
with	NULL
IxBa	NULL
»	NULL
,	NULL
;	NULL
,	NULL
a	NULL
(	NULL
Ferreira	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

Results	NULL
showed	NULL
that	NULL
IxBa	NULL
;	NULL
,	NULL
,	NULL
,	NULL
was	NULL
not	NULL
detected	NULL
in	NULL
the	NULL
9C4	NULL
clone	NULL
,	NULL
was	NULL
weakly	NULL
expressed	NULL
in	NULL
9B8	NULL
clone	NULL
and	NULL
strongly	NULL
expressed	NULL
in	NULL
X9	NULL
clone	NULL
(	NULL
Figure	NULL
1c	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
study	NULL
was	NULL
continued	NULL
with	NULL
both	NULL
9B8	NULL
and	NULL
X9	NULL
clones	NULL
.	NULL

Note	NULL
that	NULL
endogenous	NULL
IxBa	NULL
was	NULL
strongly	NULL
expressed	NULL
in	NULL
both	NULL
transfected	NULL
and	NULL
non	NULL
transfected	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
in	NULL
spite	NULL
of	NULL
the	NULL
continuous	NULL
NF-xB	NULL
activation	NULL
,	NULL
IxB	NULL
«	NULL
is	NULL
permanently	NULL
resynthesized	NULL
in	NULL
EBV	NULL
infected	NULL
cells	NULL
.	NULL

Phenotypic	NULL
analysis	NULL
of	NULL
IxB	NULL
«	NULL
transfected	NULL
clones	NULL
We	NULL
first	NULL
characterized	NULL
the	NULL
surface	NULL
phenotype	NULL
of	NULL
stably	NULL
transfected	NULL
clones	NULL
.	NULL

Our	NULL
results	NULL
did	NULL
not	NULL
evidence	NULL
any	NULL
significant	NULL
modification	NULL
in	NULL
expression	NULL
of	NULL
adhesion	NULL
molecules	NULL
(	NULL
CD11a	NULL
,	NULL
CD18	NULL
,	NULL
CD44	NULL
,	NULL
CD58	NULL
)	NULL
,	NULL
molecules	NULL
having	NULL
a	NULL
xB	NULL
site	NULL
in	NULL
their	NULL
promoter	NULL
region	NULL
(	NULL
CD25	NULL
,	NULL
CD48	NULL
,	NULL
CD54	NULL
,	NULL
HLA	NULL
class	NULL
I	NULL
and	NULL
II	NULL
molecules	NULL
)	NULL
nor	NULL
in	NULL
activation	NULL
markers	NULL
(	NULL
CD23	NULL
,	NULL
CD30	NULL
,	NULL
CD39	NULL
,	NULL
CD71	NULL
)	NULL
.	NULL

LMPI	NULL
,	NULL
EBNA2	NULL
and	NULL
BZLFIl	NULL
protein	NULL
expression	NULL
was	NULL
unaffected	NULL
in	NULL
transfected	NULL
clones	NULL
as	NULL
assessed	NULL
by	NULL
immunocytochemistry	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
next	NULL
looked	NULL
after	NULL
the	NULL
synthesis	NULL
of	NULL
three	NULL
cytokines	NULL
,	NULL
IL-2	NULL
.	NULL

IL-6	NULL
,	NULL
and	NULL
TNFa	NULL
that	NULL
are	NULL
potentially	NULL
regulated	NULL
by	NULL
NF-xB	NULL
and	NULL
could	NULL
play	NULL
a	NULL
role	NULL
in	NULL
B-cell	NULL
proliferation	NULL
.	NULL

As	NULL
control	NULL
,	NULL
we	NULL
have	NULL
tested	NULL
the	NULL
IL-10	NULL
expression	NULL
on	NULL
transfected	NULL
cells	NULL
because	NULL
its	NULL
expression	NULL
has	NULL
never	NULL
been	NULL
reported	NULL
so	NULL
far	NULL
to	NULL
be	NULL
NF-xB	NULL
dependent	NULL
.	NULL

Moreover	NULL
,	NULL
we	NULL
have	NULL
evaluated	NULL
the	NULL
synthesis	NULL
of	NULL
these	NULL
cytokines	NULL
in	NULL
both	NULL
Burkitt	NULL
EBV	NULL
(	NULL
-	NULL
)	NULL
and	NULL
EBV	NULL
(	NULL
+	NULL
)	NULL
cell	NULL
lines	NULL
.	NULL

After	NULL
incubation	NULL
of	NULL
cells	NULL
with	NULL
brefeldin	NULL
A	NULL
,	NULL
which	NULL
prevents	NULL
cytokine	NULL
secretion	NULL
by	NULL
allowing	NULL
its	NULL
accumulation	NULL
in	NULL
the	NULL
cytoplasm	NULL
,	NULL
and	NULL
intracytoplasmic	NULL
labelling	NULL
,	NULL
synthesis	NULL
of	NULL
cytokines	NULL
was	NULL
estimated	NULL
by	NULL
flow	NULL
cytometry	NULL
(	NULL
Picker	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
(	NULL
Klein	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
,	NULL
we	NULL
have	NULL
found	NULL
highest	NULL
levels	NULL
of	NULL
IL10	NULL
in	NULL
LCL	NULL
cells	NULL
and	NULL
intermediate	NULL
levels	NULL
of	NULL
IL10	NULL
in	NULL
Burkitt	NULL
EBV	NULL
(	NULL
+	NULL
)	NULL
cells	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

Intracytoplasmic	NULL
levels	NULL
of	NULL
IL10	NULL
were	NULL
similar	NULL
in	NULL
IxBa	NULL
«	NULL
transfected	NULL
cells	NULL
and	NULL
non	NULL
transfected	NULL
cells	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

IL-2	NULL
and	NULL
IL-6	NULL
intracytoplas-	NULL
SINGLE	NULL
PARAMETER	NULL
Pd	NULL
``	NULL
Ist	NULL
Emy	NULL
.	NULL

BL	NULL
EBV+	NULL
|	NULL
1	NULL
}	NULL
le	NULL
PRI	NULL
$	NULL
ﬂy	NULL
“	NULL
ml	NULL
?	NULL

“	NULL
.	NULL

«	NULL
L	NULL
!	NULL

Pﬁﬂ	NULL
,	NULL
og	NULL
SINGLE	NULL
PAReMETER	NULL
J	NULL
b	NULL
-s	NULL
27	NULL
100	NULL
1008	NULL
,	NULL
9B8	NULL
100	NULL
1008	NULL
IL10	NULL
-	NULL
-	NULL
#	NULL
»	NULL
Figure	NULL
2	NULL
IL10	NULL
intracytoplasmic	NULL
detection	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Intracytoplasmic	NULL
labelling	NULL
of	NULL
IL10	NULL
in	NULL
EBV	NULL
(	NULL
-	NULL
)	NULL
Burkitt	NULL
cell	NULL
line	NULL
DG75	NULL
(	NULL
turquoise	NULL
graph	NULL
)	NULL
,	NULL
EBV	NULL
(	NULL
+	NULL
)	NULL
Burkitt	NULL
cell	NULL
line	NULL
37505	NULL
(	NULL
purple	NULL
graph	NULL
)	NULL
and	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
PRI	NULL
(	NULL
orange	NULL
graph	NULL
)	NULL
.	NULL

Results	NULL
were	NULL
comparable	NULL
with	NULL
the	NULL
other	NULL
cell	NULL
lines	NULL
tested	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Comparison	NULL
of	NULL
intracytoplasmic	NULL
labellings	NULL
of	NULL
IL10	NULL
between	NULL
non	NULL
transfected	NULL
cells	NULL
PRI	NULL
(	NULL
orange	NULL
graph	NULL
)	NULL
and	NULL
both	NULL
X9	NULL
IxBa3	NULL
»	NULL
/36a	NULL
transfected	NULL
clone	NULL
(	NULL
blue	NULL
graph	NULL
)	NULL
and	NULL
9B8	NULL
IxBaz	NULL
»	NULL
/34a	NULL
transfected	NULL
clone	NULL
(	NULL
green	NULL
graph	NULL
)	NULL
Roles	NULL
of	NULL
NF-xB	NULL
activation	NULL
in	NULL
EBV-infected	NULL
B-lymphocytes	NULL
M	NULL
Asso-Bonnet	NULL
et	NULL
al	NULL
mic	NULL
levels	NULL
were	NULL
heterogeneous	NULL
from	NULL
one	NULL
cell	NULL
to	NULL
the	NULL
other	NULL
.	NULL

Levels	NULL
of	NULL
these	NULL
cytokines	NULL
were	NULL
not	NULL
affected	NULL
by	NULL
IxBa	NULL
transfection	NULL
in	NULL
LCL	NULL
cells	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

TNFa	NULL
was	NULL
detected	NULL
in	NULL
cytoplasm	NULL
of	NULL
both	NULL
EBV	NULL
(	NULL
-	NULL
)	NULL
and	NULL
EBV	NULL
(	NULL
+	NULL
)	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
fluorescence	NULL
intensity	NULL
of	NULL
intracytoplasmic	NULL
labelling	NULL
of	NULL
TNFa	NULL
in	NULL
EBV	NULL
(	NULL
+	NULL
)	NULL
cells	NULL
was	NULL
fourfold	NULL
higher	NULL
than	NULL
in	NULL
EBV	NULL
(	NULL
-	NULL
)	NULL
cells	NULL
(	NULL
Figure	NULL
3a	NULL
)	NULL
.	NULL

The	NULL
comparison	NULL
of	NULL
TNFa	NULL
intracytoplasmic	NULL
labelling	NULL
in	NULL
both	NULL
Burkitt	NULL
EBV	NULL
-	NULL
and	NULL
EBV	NULL
+	NULL
cells	NULL
suggested	NULL
that	NULL
EBV	NULL
infection	NULL
of	NULL
Burkitt	NULL
cells	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
strong	NULL
increase	NULL
of	NULL
TNFa	NULL
synthesis	NULL
(	NULL
Figure	NULL
3a	NULL
)	NULL
.	NULL

TNFa	NULL
intracytoplasmic	NULL
levels	NULL
were	NULL
strongly	NULL
reduced	NULL
in	NULL
both	NULL
9B8	NULL
and	NULL
X9	NULL
IxBa	NULL
transfected	NULL
clones	NULL
(	NULL
Figure	NULL
3b	NULL
)	NULL
.	NULL

Overlapping	NULL
of	NULL
fluorescence	NULL
graphs	NULL
of	NULL
TNFa	NULL
levels	NULL
in	NULL
X9	NULL
clone	NULL
and	NULL
EBV	NULL
(	NULL
-	NULL
)	NULL
Burkitt	NULL
cells	NULL
showed	NULL
that	NULL
TNFa	NULL
synthesis	NULL
levels	NULL
in	NULL
IxBa	NULL
transfected	NULL
clones	NULL
reached	NULL
down	NULL
those	NULL
of	NULL
EBV	NULL
(	NULL
-	NULL
)	NULL
cells	NULL
(	NULL
Figure	NULL
3¢	NULL
)	NULL
.	NULL

These	NULL
results	NULL
showed	NULL
that	NULL
the	NULL
loss	NULL
of	NULL
NF-xB	NULL
binding	NULL
activity	NULL
in	NULL
LCL	NULL
cells	NULL
was	NULL
associated	NULL
with	NULL
a	NULL
decrease	NULL
of	NULL
TNFa	NULL
synthesis	NULL
,	NULL
reaching	NULL
levels	NULL
similar	NULL
to	NULL
those	NULL
found	NULL
in	NULL
EBV	NULL
-	NULL
cells	NULL
.	NULL

Therefore	NULL
,	NULL
this	NULL
result	NULL
suggested	NULL
that	NULL
the	NULL
NF-xB	NULL
constitutive	NULL
activity	NULL
could	NULL
be	NULL
responsible	NULL
for	NULL
a	NULL
continuous	NULL
over-synthesis	NULL
of	NULL
TNF	NULL
«	NULL
in	NULL
EBV	NULL
infected	NULL
cells	NULL
.	NULL

I	NULL
a	NULL
®	NULL
BL	NULL
EBV+	NULL
``	NULL
|	NULL
BL	NULL
EBV-	NULL
[	NULL
\	NULL
&	NULL
|	NULL
”	NULL
ﬁt	NULL
'	NULL
b	NULL
is	NULL
st	NULL
P	NULL
I	NULL
C	NULL
%	NULL
BL	NULL
EBV	NULL
FNFG	NULL
-_-	NULL
Figure	NULL
3	NULL
-	NULL
TNFa	NULL
intracytoplasmic	NULL
detection	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Intracytoplasmic	NULL
labelling	NULL
of	NULL
TNFa	NULL
in	NULL
EBV	NULL
(	NULL
-	NULL
)	NULL
Burkitt	NULL
cell	NULL
line	NULL
DG75	NULL
(	NULL
BL	NULL
EBV	NULL
-	NULL
,	NULL
turquoise	NULL
graph	NULL
)	NULL
,	NULL
EBV	NULL
(	NULL
+	NULL
)	NULL
Burkitt	NULL
cell	NULL
line	NULL
37505	NULL
(	NULL
BL	NULL
EBV	NULL
+	NULL
,	NULL
purple	NULL
graph	NULL
)	NULL
and	NULL
in	NULL
lymmphoblastoid	NULL
cell	NULL
line	NULL
PRI	NULL
(	NULL
orange	NULL
graph	NULL
)	NULL
.	NULL

Results	NULL
were	NULL
comparable	NULL
with	NULL
the	NULL
other	NULL
cell	NULL
lines	NULL
tested	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Comparison	NULL
of	NULL
intracytoplasmic	NULL
levels	NULL
of	NULL
TNFa	NULL
between	NULL
non	NULL
transfected	NULL
cells	NULL
PRI	NULL
(	NULL
orange	NULL
graph	NULL
)	NULL
and	NULL
both	NULL
X9	NULL
transfected	NULL
clone	NULL
(	NULL
blue	NULL
graph	NULL
)	NULL
and	NULL
9B8	NULL
IxBa3	NULL
»	NULL
/35a	NULL
transfected	NULL
clone	NULL
(	NULL
green	NULL
graph	NULL
)	NULL
.	NULL

(	NULL
c	NULL
)	NULL
Comparison	NULL
of	NULL
intracytoplasmic	NULL
levels	NULL
of	NULL
TNFx	NULL
between	NULL
non	NULL
transfected	NULL
cells	NULL
PRI	NULL
(	NULL
orange	NULL
graph	NULL
)	NULL
,	NULL
X9	NULL
IxBaz	NULL
»	NULL
/s4a	NULL
transfected	NULL
clone	NULL
(	NULL
blue	NULL
graph	NULL
)	NULL
and	NULL
the	NULL
EBV	NULL
(	NULL
-	NULL
)	NULL
Burkitt	NULL
cell	NULL
line	NULL
DG75	NULL
(	NULL
turquoise	NULL
graph	NULL
)	NULL
1609	NULL
Roles	NULL
of	NULL
NF-xB	NULL
activation	NULL
in	NULL
EBV-infected	NULL
B-lymphocytes	NULL
M	NULL
Asso-Bonnet	NULL
et	NULL
al	NULL
1610	NULL
Analysis	NULL
of	NULL
proliferation	NULL
and	NULL
apoptosis	NULL
of	NULL
transfected	NULL
clones	NULL
It	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
NF-xB	NULL
activation	NULL
by	NULL
TNFa	NULL
protects	NULL
cell	NULL
from	NULL
TNF	NULL
«	NULL
induced	NULL
apoptosis	NULL
(	NULL
Beg	NULL
and	NULL
Baltimore	NULL
,	NULL
1996	NULL
;	NULL
Van	NULL
Antwerp	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Thus	NULL
we	NULL
have	NULL
investigated	NULL
the	NULL
effect	NULL
of	NULL
TNFa	NULL
on	NULL
cell	NULL
cycle	NULL
.	NULL

Cells	NULL
were	NULL
first	NULL
incubated	NULL
for	NULL
24	NULL
h	NULL
with	NULL
10	NULL
ng/ml	NULL
of	NULL
TNF	NULL
«	NULL
and	NULL
then	NULL
BrdU	NULL
incorporation	NULL
was	NULL
performed	NULL
during	NULL
4	NULL
h	NULL
and	NULL
cell	NULL
cycle	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
a	NULL
flow	NULL
cytometer	NULL
after	NULL
DNA	NULL
staining	NULL
with	NULL
propidium	NULL
iodide	NULL
(	NULL
Lowe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
presented	NULL
in	NULL
Figure	NULL
4	NULL
.	NULL

No	NULL
effect	NULL
of	NULL
TNFa	NULL
treatment	NULL
was	NULL
seen	NULL
on	NULL
non	NULL
transfected	NULL
cells	NULL
or	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
control	NULL
plasmid	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
the	NULL
number	NULL
of	NULL
BrdU	NULL
positive	NULL
cells	NULL
was	NULL
strongly	NULL
decreased	NULL
in	NULL
both	NULL
X9	NULL
and	NULL
9B8	NULL
clones	NULL
after	NULL
TNFa	NULL
treatment	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
apoptotic	NULL
cells	NULL
on	NULL
the	NULL
X9	NULL
clone	NULL
was	NULL
first	NULL
estimated	NULL
morphologically	NULL
after	NULL
May	NULL
Griinwald	NULL
Giemsa	NULL
staining	NULL
and	NULL
confirmed	NULL
using	NULL
a	NULL
test	NULL
which	NULL
evidenced	NULL
the	NULL
DNA	NULL
strand	NULL
breaks	NULL
(	NULL
Figure	NULL
5	NULL
)	NULL
.	NULL

Results	NULL
showed	NULL
that	NULL
TNFa	NULL
treatment	NULL
induced	NULL
apoptosis	NULL
in	NULL
IxBa	NULL
&	NULL
«	NULL
transfected	NULL
cells	NULL
but	NULL
not	NULL
in	NULL
non	NULL
transfected	NULL
cells	NULL
(	NULL
Figure	NULL
5	NULL
)	NULL
or	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
control	NULL
plasmid	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggested	NULL
that	NULL
the	NULL
loss	NULL
of	NULL
NF-xB	NULL
constitutive	NULL
activity	NULL
favoured	NULL
the	NULL
TNFa	NULL
transduction	NULL
pathway	NULL
leading	NULL
to	NULL
apoptosis	NULL
in	NULL
EBV	NULL
(	NULL
+	NULL
)	NULL
cells	NULL
.	NULL

Discussion	NULL
LMP1I	NULL
is	NULL
inducing	NULL
a	NULL
continuous	NULL
NF-xB	NULL
activation	NULL
.	NULL

A	NULL
recent	NULL
report	NULL
suggested	NULL
natural	NULL
deletion	NULL
variants	NULL
of	NULL
LMP1	NULL
are	NULL
submitted	NULL
to	NULL
a	NULL
selection	NULL
pressure	NULL
resulting	NULL
in	NULL
intact	NULL
NF-xB	NULL
activation	NULL
capacities	NULL
(	NULL
Rothenberger	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

This	NULL
raises	NULL
the	NULL
question	NULL
of	NULL
the	NULL
role	NULL
of	NULL
NF-KB	NULL
in	NULL
EBV	NULL
-related	NULL
lymphomagenesis	NULL
.	NULL

In	NULL
order	NULL
to	NULL
answer	NULL
this	NULL
question	NULL
we	NULL
have	NULL
inhibited	NULL
NF-xB	NULL
activity	NULL
by	NULL
transfect-ing	NULL
the	NULL
inhibitor	NULL
IxBa	NULL
«	NULL
in	NULL
LCL	NULL
cells	NULL
.	NULL

Our	NULL
results	NULL
showed	NULL
that	NULL
the	NULL
loss	NULL
of	NULL
nuclear	NULL
NF-xB	NULL
activity	NULL
was	NULL
associated	NULL
with	NULL
the	NULL
decrease	NULL
of	NULL
TNFa	NULL
synthesis	NULL
and	NULL
the	NULL
increase	NULL
of	NULL
sensitivity	NULL
to	NULL
apoptosis	NULL
after	NULL
TNFa	NULL
treatment	NULL
.	NULL

A	NULL
constitutive	NULL
NF-xB	NULL
binding	NULL
activity	NULL
was	NULL
found	NULL
in	NULL
our	NULL
EBV	NULL
positive	NULL
lymphoblastoid	NULL
cells	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
Laherty	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

Supershift	NULL
experiment	NULL
evidenced	NULL
both	NULL
p65/p50	NULL
and	NULL
p50	NULL
,	NULL
complexes	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
,	NULL
which	NULL
is	NULL
consistent	NULL
with	NULL
previous	NULL
reports	NULL
(	NULL
Herrero	NULL
ef	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

No	NULL
NF-xB	NULL
binding	NULL
activity	NULL
was	NULL
detected	NULL
in	NULL
IxBa	NULL
transfected	NULL
clones	NULL
,	NULL
which	NULL
indicated	NULL
that	NULL
both	NULL
p65/	NULL
p50	NULL
and	NULL
p50	NULL
,	NULL
complexes	NULL
were	NULL
apparently	NULL
inhibited	NULL
by	NULL
IxB	NULL
«	NULL
.	NULL

IxBx	NULL
has	NULL
been	NULL
shown	NULL
first	NULL
to	NULL
target	NULL
p65	NULL
containing	NULL
dimers	NULL
,	NULL
whereas	NULL
no	NULL
inhibitory	NULL
effect	NULL
was	NULL
seen	NULL
on	NULL
the	NULL
binding	NULL
of	NULL
p50	NULL
,	NULL
dimers	NULL
(	NULL
Baeuerle	NULL
and	NULL
Baltimore	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

However	NULL
,	NULL
characterization	NULL
of	NULL
interactions	NULL
between	NULL
IxBa	NULL
and	NULL
p50	NULL
or	NULL
p65	NULL
showed	NULL
that	NULL
,	NULL
in	NULL
vitro	NULL
,	NULL
IxBa	NULL
may	NULL
weakly	NULL
interact	NULL
with	NULL
p50	NULL
,	NULL
homodimers	NULL
and	NULL
partly	NULL
inhibit	NULL
its	NULL
binding	NULL
activity	NULL
(	NULL
Liou	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
transfection	NULL
of	NULL
IxBa	NULL
«	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
a	NULL
relocalization	NULL
of	NULL
p50	NULL
into	NULL
the	NULL
cytoplasm	NULL
(	NULL
Zabel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
p105	NULL
gene	NULL
expression	NULL
is	NULL
regulated	NULL
by	NULL
NF-xB	NULL
(	NULL
Ten	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
and	NULL
LMPI	NULL
induces	NULL
p105	NULL
through	NULL
NF-xB	NULL
activation	NULL
(	NULL
Herrero	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Since	NULL
our	NULL
EMSA	NULL
experiments	NULL
were	NULL
done	NULL
on	NULL
nuclear	NULL
extracts	NULL
,	NULL
the	NULL
lack	NULL
of	NULL
detection	NULL
of	NULL
any	NULL
Rel/NF-xB	NULL
complexes	NULL
in	NULL
our	NULL
transfected	NULL
clones	NULL
may	NULL
be	NULL
explained	NULL
by	NULL
three	NULL
hypothesis	NULL
which	NULL
are	NULL
not	NULL
exclusive	NULL
:	NULL
(	NULL
i	NULL
)	NULL
IxB	NULL
«	NULL
may	NULL
translocate	NULL
in	NULL
the	NULL
nucleus	NULL
(	NULL
Arenzana-Seisdedos	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Cressman	NULL
and	NULL
Taub	NULL
,	NULL
1993	NULL
;	NULL
Zabel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
where	NULL
it	NULL
inhibits	NULL
the	NULL
DNA	NULL
binding	NULL
of	NULL
Rel/	NULL
NF-xB	NULL
complexes	NULL
with	NULL
an	NULL
efficacy	NULL
related	NULL
to	NULL
its	NULL
differential	NULL
affinity	NULL
to	NULL
these	NULL
complexes	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
IxBa	NULL
may	NULL
relocate	NULL
Rel/NF-xB	NULL
complexes	NULL
into	NULL
the	NULL
cytoplasm	NULL
,	NULL
including	NULL
p50	NULL
,	NULL
complexes	NULL
and	NULL
(	NULL
iii	NULL
)	NULL
the	NULL
constitutive	NULL
expression	NULL
of	NULL
the	NULL
stably	NULL
transfected	NULL
mutated	NULL
IxBOz3	NULL
>	NULL
/ea	NULL
may	NULL
down	NULL
regulate	NULL
the	NULL
p105	NULL
gene	NULL
transcription	NULL
leading	NULL
to	NULL
a	NULL
decrease	NULL
in	NULL
the	NULL
total	NULL
amount	NULL
of	NULL
some	NULL
Rel/NF-xB	NULL
proteins	NULL
such	NULL
as	NULL
p50	NULL
.	NULL

Except	NULL
for	NULL
TNF	NULL
«	NULL
,	NULL
we	NULL
did	NULL
not	NULL
evidence	NULL
significative	NULL
changes	NULL
in	NULL
expression	NULL
of	NULL
various	NULL
genes	NULL
that	NULL
could	NULL
be	NULL
theoretically	NULL
regulated	NULL
by	NULL
NF-xB	NULL
complexes	NULL
such	NULL
as	NULL
CD25	NULL
,	NULL
CD48	NULL
,	NULL
CD54	NULL
,	NULL
HLA	NULL
class	NULL
I	NULL
and	NULL
II	NULL
molecules	NULL
or	NULL
IL-1	NULL
,	NULL
2	NULL
or	NULL
6	NULL
.	NULL

This	NULL
could	NULL
be	NULL
due	NULL
to	NULL
a	NULL
weak	NULL
in	NULL
vivo	NULL
NF-xB	NULL
dependence	NULL
of	NULL
genes	NULL
analysed	NULL
in	NULL
EBV	NULL
infected	NULL
B	NULL
cells	NULL
.	NULL

Alternatively	NULL
,	NULL
it	NULL
could	NULL
reflect	NULL
a	NULL
mechanism	NULL
by	NULL
which	NULL
EBV	NULL
infected	NULL
cells	NULL
escape	NULL
from	NULL
the	NULL
control	NULL
of	NULL
gene	NULL
expression	NULL
by	NULL
cellular	NULL
factors	NULL
.	NULL

One	NULL
interesting	NULL
example	NULL
is	NULL
related	NULL
to	NULL
the	NULL
IL-6	NULL
gene	NULL
regulation	NULL
and	NULL
its	NULL
relationships	NULL
with	NULL
NF-xB	NULL
and	NULL
EBNA2Z	NULL
.	NULL

Regulation	NULL
of	NULL
IL-6	NULL
may	NULL
involve	NULL
NF-xB	NULL
(	NULL
Libermann	NULL
and	NULL
Baltimore	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

However	NULL
,	NULL
IL-6	NULL
gene	NULL
transcription	NULL
could	NULL
potentially	NULL
become	NULL
NF-xB	NULL
independent	NULL
in	NULL
EBV	NULL
infected	NULL
cells	NULL
because	NULL
of	NULL
interference	NULL
between	NULL
EBNA2	NULL
and	NULL
xB	NULL
sites	NULL
.	NULL

EBNA2	NULL
targets	NULL
the	NULL
RBP-Jx	NULL
cellular	NULL
factor	NULL
(	NULL
Grossman	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Henkel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Zimber-Strobl	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

RBP-Jx	NULL
is	NULL
involved	NULL
in	NULL
negative	NULL
regulation	NULL
of	NULL
genes	NULL
(	NULL
Hsich	NULL
and	NULL
Hayward	NULL
,	NULL
1995	NULL
;	NULL
Waltzer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Binding	NULL
of	NULL
EBNA2	NULL
to	NULL
RBP-Jx	NULL
leads	NULL
to	NULL
the	NULL
formation	NULL
of	NULL
a	NULL
complex	NULL
which	NULL
activates	NULL
gene	NULL
transcription	NULL
through	NULL
the	NULL
transcriptional	NULL
domain	NULL
of	NULL
EBNA2	NULL
.	NULL

This	NULL
complex	NULL
is	NULL
able	NULL
to	NULL
activate	NULL
the	NULL
transcription	NULL
of	NULL
numerous	NULL
cellular	NULL
genes	NULL
such	NULL
as	NULL
CD23	NULL
as	NULL
well	NULL
as	NULL
in	NULL
the	NULL
LMP	NULL
I1	NULL
gene	NULL
of	NULL
the	NULL
EBV	NULL
episome	NULL
(	NULL
Grossman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Henkel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Zimber-Strobl	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

A	NULL
recent	NULL
report	NULL
showed	NULL
that	NULL
RBP-Jx	NULL
is	NULL
also	NULL
able	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
xB	NULL
site	NULL
of	NULL
the	NULL
IL-6	NULL
gene	NULL
and	NULL
is	NULL
responsible	NULL
for	NULL
low	NULL
basal	NULL
levels	NULL
of	NULL
IL-6	NULL
gene	NULL
transcription	NULL
in	NULL
fibroblastic	NULL
cells	NULL
(	NULL
Plaisance	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
EBV-infected	NULL
cells	NULL
,	NULL
EBNA2	NULL
could	NULL
target	NULL
the	NULL
RBP-Jk	NULL
bound	NULL
to	NULL
the	NULL
xB	NULL
site	NULL
of	NULL
the	NULL
IL-6	NULL
gene	NULL
,	NULL
leading	NULL
to	NULL
its	NULL
over-transcription	NULL
in	NULL
an	NULL
NF-xB	NULL
independent	NULL
manner	NULL
(	NULL
Plaisance	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

This	NULL
example	NULL
shows	NULL
the	NULL
possibility	NULL
for	NULL
EBV	NULL
to	NULL
render	NULL
transcription	NULL
of	NULL
some	NULL
xB-regulated	NULL
genes	NULL
independent	NULL
of	NULL
NF-xB	NULL
activation	NULL
even	NULL
if	NULL
NF-xB	NULL
is	NULL
continuously	NULL
activated	NULL
by	NULL
EBV	NULL
.	NULL

We	NULL
found	NULL
a	NULL
correlation	NULL
between	NULL
a	NULL
decrease	NULL
of	NULL
TNFa	NULL
synthesis	NULL
and	NULL
the	NULL
loss	NULL
of	NULL
NF-xB	NULL
binding	NULL
activity	NULL
in	NULL
our	NULL
IxBa	NULL
«	NULL
transfected	NULL
clones	NULL
.	NULL

One	NULL
of	NULL
the	NULL
first	NULL
reports	NULL
on	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
TNF	NULL
«	NULL
gene	NULL
transcription	NULL
evidenced	NULL
the	NULL
presence	NULL
of	NULL
xB	NULL
sites	NULL
in	NULL
its	NULL
promoter	NULL
region	NULL
and	NULL
showed	NULL
that	NULL
this	NULL
xB	NULL
transcriptional	NULL
activity	NULL
is	NULL
correlated	NULL
with	NULL
a	NULL
constitutive	NULL
NF-xB	NULL
binding	NULL
activity	NULL
in	NULL
macrophages	NULL
(	NULL
Collart	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Shakhov	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Three	NULL
xB	NULL
sites	NULL
have	NULL
been	NULL
found	NULL
in	NULL
the	NULL
promoter	NULL
region	NULL
of	NULL
the	NULL
human	NULL
TNFa	NULL
gene	NULL
(	NULL
Goldfeld	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

These	NULL
xB	NULL
sites	NULL
are	NULL
able	NULL
to	NULL
bind	NULL
NF-xB	NULL
complexes	NULL
.	NULL

But	NULL
,	NULL
little	NULL
or	NULL
no	NULL
effect	NULL
has	NULL
been	NULL
observed	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
transcriptional	NULL
activity	NULL
through	NULL
the	NULL
TNFa	NULL
promoter	NULL
when	NULL
xB	NULL
sites	NULL
are	NULL
deleted	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
xB	NULL
sites	NULL
of	NULL
the	NULL
TNFa	NULL
promoter	NULL
depends	NULL
on	NULL
the	NULL
cell	NULL
type	NULL
.	NULL

These	NULL
xB	NULL
sites	NULL
are	NULL
inactive	NULL
in	NULL
T-cells	NULL
(	NULL
Goldfeld	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

However	NULL
,	NULL
multimerization	NULL
of	NULL
the	NULL
xB	NULL
sites	NULL
of	NULL
the	NULL
TNFa	NULL
promoter	NULL
region	NULL
is	NULL
able	NULL
to	NULL
confer	NULL
an	NULL
inducible	NULL
transcriptional	NULL
activity	NULL
of	NULL
a	NULL
reporter	NULL
gene	NULL
after	NULL
PMA	NULL
stimulation	NULL
in	NULL
the	NULL
Roles	NULL
of	NULL
NF-xB	NULL
activation	NULL
in	NULL
EBV-infected	NULL
B-lymphocytes	NULL
M	NULL
Asso-Bonnet	NULL
et	NULL
al	NULL
1611	NULL
Raji	NULL
cell	NULL
line	NULL
(	NULL
an	NULL
EBV	NULL
positive	NULL
Burkitt	NULL
cell	NULL
line	NULL
)	NULL
(	NULL
Goldfeld	NULL
levels	NULL
in	NULL
EBV	NULL
negative	NULL
Burkitt	NULL
cells	NULL
Two	NULL
reports	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
showed	NULL
that	NULL
,	NULL
in	NULL
IxBa	NULL
transfected	NULL
evidenced	NULL
relationships	NULL
between	NULL
the	NULL
loss	NULL
of	NULL
NF-xB	NULL
cells	NULL
,	NULL
the	NULL
loss	NULL
of	NULL
NF-xB	NULL
activity	NULL
was	NULL
associated	NULL
with	NULL
a	NULL
_	NULL
activity	NULL
and	NULL
the	NULL
decrease	NULL
of	NULL
TNFx	NULL
gene	NULL
expression	NULL
.	NULL

dramatic	NULL
decrease	NULL
of	NULL
TNFa	NULL
synthesis	NULL
reaching	NULL
TNFa	NULL
_	NULL
Both	NULL
were	NULL
using	NULL
the	NULL
pharmacological	NULL
property	NULL
of	NULL
Aspirin	NULL
a	NULL
1800	NULL
1008	NULL
100	NULL
180	NULL
51	NULL
%	NULL
rir	NULL
10	NULL
C	NULL
2081.20	NULL
)	NULL
rir	NULL
roc	NULL
18	NULL
z00	NULL
408	NULL
cee	NULL
see	NULL
1008	NULL
6	NULL
zen	NULL
489	NULL
cen	NULL
gas	NULL
1000	NULL
ECCH	NULL
1080	NULL
108	NULL
Fold	NULL
27	NULL
%	NULL
PLi	NULL
LoG	NULL
10	NULL
CA28X128	NULL
)	NULL
Fla	NULL
Loc	NULL
18	NULL
Grzize	NULL
BrdU	NULL
incorporation	NULL
200	NULL
«	NULL
00	NULL
coa	NULL
ses	NULL
1000	NULL
200	NULL
4180	NULL
cee	NULL
sas	NULL
1000	NULL
700	NULL
<	NULL
coo	NULL
4B	NULL
soo	NULL
JB	NULL
aso	NULL
+8	NULL
300	NULL
4	NULL
200	NULL
4	NULL
Bf	NULL
100	NULL
4	NULL
Number	NULL
of	NULL
BrdU	NULL
positive	NULL
cells	NULL
*10€3/ml	NULL
xo	NULL
NT	NULL
noone	NULL
6s	NULL
NT	NULL
PRINT	NULL
12F8	NULL
NT	NULL
9B3	NULL
TNF	NULL
240.	NULL
xo	NULL
TNF	NULL
248	NULL
PRI	NULL
TNF	NULL
246	NULL
268	NULL
INF	NULL
24k	NULL
Figure	NULL
4	NULL
-	NULL
Analysis	NULL
of	NULL
BrdU	NULL
incorporation	NULL
in	NULL
IxBa	NULL
transfected	NULL
cells	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Comparison	NULL
of	NULL
BrdU	NULL
incorporation	NULL
in	NULL
non	NULL
transfected	NULL
LCL	NULL
PRI	NULL
cells	NULL
(	NULL
graphs	NULL
A	NULL
and	NULL
B	NULL
)	NULL
and	NULL
the	NULL
X9	NULL
IxBa3	NULL
;	NULL
/35a	NULL
transfected	NULL
clone	NULL
(	NULL
graphs	NULL
C	NULL
and	NULL
D	NULL
)	NULL
in	NULL
absence	NULL
(	NULL
graphs	NULL
A	NULL
and	NULL
C	NULL
)	NULL
or	NULL
in	NULL
presence	NULL
of	NULL
10	NULL
ng/ml	NULL
of	NULL
TNF	NULL
«	NULL
for	NULL
24	NULL
h	NULL
(	NULL
graphs	NULL
B	NULL
and	NULL
D	NULL
)	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
cells	NULL
having	NULL
incorporated	NULL
BrdU	NULL
is	NULL
indicated	NULL
in	NULL
each	NULL
graph	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Quantification	NULL
of	NULL
the	NULL
number	NULL
of	NULL
cells/ml	NULL
having	NULL
incorporated	NULL
BrdU	NULL
in	NULL
absence	NULL
(	NULL
NT	NULL
)	NULL
or	NULL
in	NULL
presence	NULL
of	NULL
100	NULL
U/ml	NULL
of	NULL
TNFa	NULL
for	NULL
24	NULL
h	NULL
(	NULL
TNF	NULL
24	NULL
h	NULL
)	NULL
for	NULL
the	NULL
non	NULL
transfected	NULL
PRI	NULL
LCL	NULL
cells	NULL
,	NULL
the	NULL
12F8	NULL
clone	NULL
transfected	NULL
with	NULL
the	NULL
control	NULL
plasmid	NULL
and	NULL
the	NULL
X9	NULL
and	NULL
9B8	NULL
IxBoz	NULL
;	NULL
/35a	NULL
transfected	NULL
clones	NULL
Roles	NULL
of	NULL
NF-xB	NULL
activation	NULL
in	NULL
EBV-infected	NULL
B-lymphocytes	NULL
M	NULL
Asso-Bonnet	NULL
et	NULL
al	NULL
1612	NULL
~a	NULL
%	NULL
of	NULL
apoptotic	NULL
cells	NULL
40	NULL
4	NULL
Non	NULL
transfected	NULL
cells	NULL
m	NULL
-	NULL
IxBo	NULL
transfected	NULL
cells	NULL
TNF	NULL
incubation	NULL
Figure	NULL
5	NULL
Analysis	NULL
of	NULL
apoptosis	NULL
in	NULL
IxBa	NULL
transfected	NULL
clones	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Detection	NULL
of	NULL
apoptosis	NULL
TNF	NULL
treatment	NULL
for	NULL
8	NULL
h	NULL
;	NULL
panels	NULL
A	NULL
to	NULL
D	NULL
,	NULL
MGG	NULL
staining	NULL
of	NULL
cells	NULL
;	NULL
panels	NULL
E	NULL
and	NULL
F	NULL
,	NULL
fluorescence	NULL
detection	NULL
of	NULL
DNA	NULL
strand	NULL
break	NULL
;	NULL
panels	NULL
A	NULL
and	NULL
B	NULL
:	NULL
non	NULL
transfected	NULL
LCL	NULL
cells	NULL
;	NULL
panels	NULL
C	NULL
to	NULL
F	NULL
X9	NULL
IxBaz	NULL
;	NULL
/35a	NULL
transfected	NULL
clone	NULL
;	NULL
panels	NULL
A	NULL
,	NULL
C	NULL
and	NULL
E	NULL
:	NULL
no	NULL
treatment	NULL
;	NULL
panels	NULL
B	NULL
,	NULL
D	NULL
and	NULL
F	NULL
:	NULL
TNFa	NULL
for	NULL
8	NULL
h.	NULL
Some	NULL
examples	NULL
of	NULL
apoptotic	NULL
cells	NULL
are	NULL
pointed	NULL
by	NULL
the	NULL
arrows	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Kinetics	NULL
of	NULL
apoptosis	NULL
in	NULL
non	NULL
transfected	NULL
LCL	NULL
PRI	NULL
cells	NULL
and	NULL
in	NULL
X9	NULL
IxBa3	NULL
;	NULL
/35a	NULL
transfected	NULL
cells	NULL
after	NULL
TNF	NULL
«	NULL
treatment	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
apoptotic	NULL
cells	NULL
is	NULL
indicated	NULL
by	NULL
the	NULL
grey	NULL
bars	NULL
for	NULL
the	NULL
PRI	NULL
LCL	NULL
and	NULL
the	NULL
black	NULL
bars	NULL
for	NULL
the	NULL
X9	NULL
IxBa3	NULL
;	NULL
/35a	NULL
transfected	NULL
clone	NULL
which	NULL
is	NULL
to	NULL
inhibit	NULL
NF-xB	NULL
by	NULL
stabilizing	NULL
IxBa	NULL
«	NULL
.	NULL

Both	NULL
reports	NULL
showed	NULL
that	NULL
TNFa	NULL
gene	NULL
transcription	NULL
is	NULL
NF-xB	NULL
dependent	NULL
in	NULL
macrophages	NULL
(	NULL
Osnes	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Shackelford	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Another	NULL
report	NULL
showed	NULL
that	NULL
levels	NULL
of	NULL
TNFa	NULL
synthesis	NULL
are	NULL
correlated	NULL
with	NULL
levels	NULL
of	NULL
NF-KB	NULL
binding	NULL
activity	NULL
in	NULL
human	NULL
B-cells	NULL
(	NULL
Coral	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
Aspirin	NULL
blocks	NULL
EBV-induced	NULL
B-cell	NULL
proliferation	NULL
in	NULL
vitro	NULL
(	NULL
Sugano	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Together	NULL
with	NULL
our	NULL
results	NULL
,	NULL
this	NULL
strongly	NULL
suggests	NULL
that	NULL
the	NULL
TNFa	NULL
gene	NULL
could	NULL
be	NULL
a	NULL
genuine	NULL
target	NULL
of	NULL
Rel/NF-xB	NULL
complexes	NULL
in	NULL
some	NULL
defined	NULL
cell	NULL
types	NULL
such	NULL
as	NULL
macrophages	NULL
and	NULL
B-cells	NULL
and	NULL
that	NULL
continuous	NULL
NF-xB	NULL
activation	NULL
in	NULL
EBV-infected	NULL
B-cells	NULL
by	NULL
LMP	NULL
1	NULL
is	NULL
responsible	NULL
for	NULL
a	NULL
continuous	NULL
over-expression	NULL
of	NULL
the	NULL
TNFax	NULL
gene	NULL
.	NULL

Constitutive	NULL
NF-xB	NULL
binding	NULL
activity	NULL
was	NULL
hardly	NULL
detectable	NULL
in	NULL
EBV	NULL
negative	NULL
Burkitt	NULL
cells	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
after	NULL
brefeldin	NULL
A	NULL
incubation	NULL
of	NULL
these	NULL
cells	NULL
(	NULL
which	NULL
blocks	NULL
the	NULL
cytokine	NULL
secretion	NULL
)	NULL
,	NULL
accumulation	NULL
of	NULL
TNFa	NULL
protein	NULL
was	NULL
still	NULL
detectable	NULL
in	NULL
both	NULL
IxBa	NULL
«	NULL
transfected	NULL
clones	NULL
and	NULL
EBV	NULL
negatives	NULL
Burkitt-cells	NULL
,	NULL
suggesting	NULL
that	NULL
other	NULL
components	NULL
of	NULL
the	NULL
TNFa	NULL
regulatory	NULL
region	NULL
are	NULL
also	NULL
playing	NULL
important	NULL
roles	NULL
in	NULL
the	NULL
transcription	NULL
of	NULL
the	NULL
TNFx	NULL
gene	NULL
.	NULL

Indeed	NULL
,	NULL
TNFa	NULL
gene	NULL
expression	NULL
may	NULL
be	NULL
NF-xB	NULL
independent	NULL
in	NULL
mice	NULL
cells	NULL
treated	NULL
with	NULL
LPS	NULL
(	NULL
Goldfeld	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
or	NULL
in	NULL
human	NULL
pernicious	NULL
malaria	NULL
(	NULL
McGuire	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
our	NULL
results	NULL
suggest	NULL
that	NULL
Rel/NF-xB	NULL
complexes	NULL
could	NULL
play	NULL
a	NULL
role	NULL
in	NULL
over-expression	NULL
of	NULL
TNFa	NULL
gene	NULL
in	NULL
EBV-infected	NULL
B-cells	NULL
.	NULL

The	NULL
role	NULL
of	NULL
NF-xB	NULL
complexes	NULL
in	NULL
TNFa	NULL
signalling	NULL
seems	NULL
to	NULL
be	NULL
at	NULL
least	NULL
to	NULL
protect	NULL
cells	NULL
from	NULL
apoptosis	NULL
induced	NULL
by	NULL
the	NULL
same	NULL
TNFx	NULL
(	NULL
Beg	NULL
and	NULL
Baltimore	NULL
,	NULL
1996	NULL
;	NULL
Van	NULL
Antwerp	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
showed	NULL
that	NULL
the	NULL
loss	NULL
of	NULL
NF-xB	NULL
binding	NULL
activity	NULL
in	NULL
EBV	NULL
infected	NULL
cells	NULL
made	NULL
them	NULL
sensitive	NULL
to	NULL
TNFx-induced	NULL
apoptosis	NULL
.	NULL

LMPI1	NULL
protein	NULL
is	NULL
mimicking	NULL
the	NULL
TNFRII	NULL
activation	NULL
cascade	NULL
by	NULL
aggregating	NULL
TRAF2	NULL
molecules	NULL
,	NULL
leading	NULL
to	NULL
NF-xB	NULL
activation	NULL
and	NULL
cell	NULL
proliferation	NULL
(	NULL
Kaye	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
suggest	NULL
that	NULL
TNF	NULL
gene	NULL
could	NULL
be	NULL
a	NULL
target	NULL
of	NULL
NF-xB	NULL
in	NULL
EBV-infected	NULL
cells	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
seems	NULL
likely	NULL
that	NULL
continuous	NULL
NF-xB	NULL
activation	NULL
in	NULL
EBV-infected	NULL
cells	NULL
would	NULL
protect	NULL
cells	NULL
from	NULL
adverse	NULL
cytotoxic	NULL
effects	NULL
of	NULL
autocrine	NULL
TNFa	NULL
secretion	NULL
,	NULL
and	NULL
favour	NULL
cell	NULL
proliferation	NULL
induced	NULL
by	NULL
permanent	NULL
TRAF2	NULL
molecule	NULL
cascade	NULL
activation	NULL
.	NULL

Roles	NULL
of	NULL
TNF	NULL
«	NULL
in	NULL
lymphomagenesis	NULL
are	NULL
highly	NULL
suspected	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
high	NULL
levels	NULL
of	NULL
TNFx	NULL
in	NULL
plasma	NULL
of	NULL
patients	NULL
having	NULL
non	NULL
Hodgkin	NULL
's	NULL
lymphomas	NULL
is	NULL
predictive	NULL
of	NULL
a	NULL
poor	NULL
prognosis	NULL
(	NULL
Macia	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Salles	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Warzocha	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997a	NULL
,	NULL
b	NULL
)	NULL
.	NULL

The	NULL
proliferative	NULL
effect	NULL
of	NULL
TNFa	NULL
on	NULL
B-cells	NULL
is	NULL
well	NULL
known	NULL
(	NULL
Cordingley	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Jelinek	NULL
and	NULL
Lipsky	NULL
,	NULL
1987	NULL
;	NULL
Kehrl	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
,	NULL
EBV	NULL
infection	NULL
is	NULL
associated	NULL
with	NULL
TNFa	NULL
secretion	NULL
(	NULL
Jochems	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Klein	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Sung	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
suggest	NULL
that	NULL
TNFa	NULL
could	NULL
be	NULL
a	NULL
target	NULL
gene	NULL
of	NULL
NF-xB	NULL
in	NULL
EBV-infected	NULL
cells	NULL
.	NULL

By	NULL
protecting	NULL
cells	NULL
against	NULL
TNFw-induced	NULL
apoptosis	NULL
,	NULL
continuous	NULL
NF-xB	NULL
activation	NULL
may	NULL
therefore	NULL
favour	NULL
a	NULL
synergy	NULL
between	NULL
EBV	NULL
and	NULL
TNFa	NULL
in	NULL
B-cell	NULL
proliferation	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Cells	NULL
Two	NULL
EBV-Burkitt	NULL
cell	NULL
lines	NULL
(	NULL
Iarc/BL31	NULL
from	NULL
Pr	NULL
Lenoir	NULL
,	NULL
CIRC	NULL
,	NULL
Lyon	NULL
,	NULL
France	NULL
,	NULL
and	NULL
DG75	NULL
)	NULL
,	NULL
three	NULL
EBV	NULL
+	NULL
Burkitt	NULL
cell	NULL
Roles	NULL
of	NULL
NF-xB	NULL
activation	NULL
in	NULL
EBV-infected	NULL
B-lymphocytes	NULL
M	NULL
Asso-Bonnet	NULL
et	NULL
al	NULL
lines	NULL
(	NULL
34831	NULL
and	NULL
Iarc/BL36	NULL
from	NULL
Pr	NULL
Lenoir	NULL
and	NULL
RAJT	NULL
)	NULL
and	NULL
five	NULL
EBV	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
(	NULL
ARB	NULL
,	NULL
PRI	NULL
from	NULL
Dr	NULL
F	NULL
Praz	NULL
,	NULL
IOCMH	NULL
,	NULL
Bobigny	NULL
,	NULL
France	NULL
and	NULL
1462	NULL
,	NULL
F263	NULL
and	NULL
10847	NULL
from	NULL
Pr	NULL
Lenoir	NULL
)	NULL
were	NULL
cultured	NULL
continuously	NULL
in	NULL
RPMI	NULL
1640	NULL
with	NULL
standard	NULL
concentration	NULL
of	NULL
L-glutamine	NULL
,	NULL
antibiotics	NULL
and	NULL
10	NULL
%	NULL
foetal	NULL
calf	NULL
serum	NULL
.	NULL

The	NULL
A3	NULL
clone	NULL
described	NULL
previously	NULL
(	NULL
Ferreira	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
and	NULL
corresponds	NULL
to	NULL
HPB-ALL	NULL
parental	NULL
cells	NULL
stably	NULL
transfected	NULL
cells	NULL
with	NULL
the	NULL
cDNA	NULL
.	NULL

Plasmid	NULL
constructs	NULL
The	NULL
plasmid	NULL
construct	NULL
pCMV-	NULL
has	NULL
been	NULL
described	NULL
by	NULL
Zabel	NULL
er	NULL
al	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
,	NULL
modified	NULL
by	NULL
Traenkner	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
and	NULL
is	NULL
a	NULL
kind	NULL
gift	NULL
of	NULL
PA	NULL
Baeuerle	NULL
.	NULL

It	NULL
consists	NULL
in	NULL
IxB	NULL
«	NULL
cDNA	NULL
,	NULL
in	NULL
which	NULL
serines	NULL
at	NULL
position	NULL
32	NULL
and	NULL
36	NULL
were	NULL
substituted	NULL
by	NULL
alanines	NULL
,	NULL
cloned	NULL
the	NULL
peDNA3	NULL
vector	NULL
from	NULL
Invitrogen	NULL
.	NULL

Control	NULL
plasmid	NULL
consists	NULL
in	NULL
the	NULL
empty	NULL
plasmid	NULL
pecDNA3	NULL
.	NULL

PGL2-Luc	NULL
plasmid	NULL
was	NULL
purchased	NULL
from	NULL
Promega	NULL
(	NULL
Lyon	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Transfection	NULL
and	NULL
cloning	NULL
of	NULL
cells	NULL
Since	NULL
LCLs	NULL
are	NULL
known	NULL
to	NULL
be	NULL
refractory	NULL
to	NULL
stable	NULL
transfection	NULL
,	NULL
a	NULL
preliminary	NULL
step	NULL
has	NULL
consisted	NULL
of	NULL
the	NULL
analysing	NULL
of	NULL
cloning	NULL
and	NULL
transfection	NULL
conditions	NULL
of	NULL
five	NULL
different	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
,	NULL
that	NULL
were	NULL
homogeneous	NULL
in	NULL
terms	NULL
of	NULL
phenotype	NULL
and	NULL
NF-xB	NULL
constitutive	NULL
activity	NULL
.	NULL

Transient	NULL
transfection	NULL
assays	NULL
using	NULL
the	NULL
Biorad*	NULL
electro-porator	NULL
(	NULL
Biorad	NULL
,	NULL
Ivry/Seine	NULL
,	NULL
France	NULL
)	NULL
with	NULL
the	NULL
PGL2-Luc	NULL
plasmid	NULL
(	NULL
which	NULL
constitutively	NULL
express	NULL
the	NULL
luciferase	NULL
gene	NULL
)	NULL
allowed	NULL
us	NULL
to	NULL
optimize	NULL
the	NULL
electroporation	NULL
conditions	NULL
,	NULL
that	NULL
were	NULL
250	NULL
V	NULL
and	NULL
960	NULL
uF	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
plasmid	NULL
per	NULL
10	NULL
million	NULL
cells	NULL
.	NULL

Three	NULL
out	NULL
of	NULL
the	NULL
five	NULL
LCLs	NULL
tested	NULL
(	NULL
PRI	NULL
,	NULL
F263	NULL
and	NULL
10847	NULL
)	NULL
appeared	NULL
to	NULL
be	NULL
easy	NULL
to	NULL
transfect	NULL
.	NULL

Furthermore	NULL
,	NULL
these	NULL
three	NULL
LCLs	NULL
were	NULL
easy	NULL
to	NULL
clone	NULL
by	NULL
limiting	NULL
dilution	NULL
.	NULL

Therefore	NULL
,	NULL
these	NULL
three	NULL
LCLs	NULL
were	NULL
stably	NULL
transfected	NULL
with	NULL
the	NULL
pCMV-IxBa	NULL
;	NULL
»	NULL
&	NULL
,	NULL
a	NULL
construct	NULL
and	NULL
its	NULL
control	NULL
,	NULL
the	NULL
pecDNA3	NULL
plasmid	NULL
.	NULL

After	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
culture	NULL
medium	NULL
at	NULL
10°	NULL
per	NULL
ml	NULL
and	NULL
cultured	NULL
48	NULL
h	NULL
without	NULL
the	NULL
selection	NULL
antibiotic	NULL
.	NULL

Cells	NULL
were	NULL
than	NULL
plated	NULL
at	NULL
limiting	NULL
dilution	NULL
on	NULL
two	NULL
96	NULL
wells	NULL
plates	NULL
and	NULL
cultured	NULL
with	NULL
G418	NULL
antibiotic	NULL
at	NULL
0.5	NULL
mg/ml	NULL
.	NULL

Three	NULL
series	NULL
of	NULL
transfection	NULL
were	NULL
done	NULL
with	NULL
both	NULL
plasmid	NULL
and	NULL
the	NULL
control	NULL
pcDNA3	NULL
,	NULL
which	NULL
corresponds	NULL
to	NULL
576	NULL
ensemenced	NULL
well	NULL
.	NULL

Thirty-five	NULL
clones	NULL
with	NULL
pCMV-IxBa	NULL
;	NULL
;	NULL
,	NULL
;	NULL
,	NULL
a	NULL
and	NULL
30	NULL
clones	NULL
with	NULL
pcDNA3	NULL
were	NULL
growing	NULL
in	NULL
selective	NULL
conditions	NULL
for	NULL
the	NULL
LCL	NULL
PRI	NULL
only	NULL
.	NULL

Southern	NULL
blot	NULL
using	NULL
the	NULL
IxBa	NULL
;	NULL
;	NULL
>	NULL
4	NULL
,	NULL
a	NULL
,	NULL
cDNA	NULL
as	NULL
a	NULL
probe	NULL
evidenced	NULL
the	NULL
integration	NULL
of	NULL
the	NULL
transgene	NULL
cDNA	NULL
in	NULL
three	NULL
out	NULL
of	NULL
the	NULL
33	NULL
clones	NULL
transfected	NULL
with	NULL
the	NULL
CMV-IxB	NULL
«	NULL
plasmid	NULL
,	NULL
named	NULL
9C4	NULL
,	NULL
9B8	NULL
and	NULL
X9	NULL
.	NULL

Protein	NULL
extracts	NULL
and	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
Nuclear	NULL
and	NULL
cytosolic	NULL
proteins	NULL
were	NULL
extracted	NULL
in	NULL
parallel	NULL
from	NULL
cells	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Feuillard	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

The	NULL
xB	NULL
oligonucleotide	NULL
was	NULL
purchased	NULL
from	NULL
Eurogenetec	NULL
(	NULL
Serain	NULL
,	NULL
Belgium	NULL
)	NULL
and	NULL
corresponds	NULL
to	NULL
the	NULL
tandem	NULL
xB	NULL
sequence	NULL
(	NULL
PRE	NULL
)	NULL
from	NULL
the	NULL
HIV	NULL
LTR	NULL
(	NULL
Korner	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Wu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

Gel	NULL
shift	NULL
experiment	NULL
were	NULL
performed	NULL
with	NULL
20	NULL
ug	NULL
of	NULL
nuclear	NULL
proteins	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Feuillard	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

Supershift	NULL
experiments	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
Ferreira	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
and	NULL
immune	NULL
serum	NULL
were	NULL
diluted	NULL
at	NULL
1/10	NULL
(	NULL
immune	NULL
serum	NULL
no	NULL
1141	NULL
for	NULL
p50	NULL
,	NULL
1226	NULL
and	NULL
1207	NULL
for	NULL
p65	NULL
,	NULL
1136	NULL
for	NULL
c-Rel	NULL
,	NULL
1267	NULL
for	NULL
p52	NULL
and	NULL
1319	NULL
for	NULL
RelB	NULL
were	NULL
generously	NULL
gifted	NULL
by	NULL
N	NULL
Rice	NULL
,	NULL
NCI	NULL
,	NULL
Frederick	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

Western	NULL
blot	NULL
Cytosolic	NULL
proteins	NULL
(	NULL
50	NULL
ug	NULL
)	NULL
were	NULL
fractionated	NULL
on	NULL
a	NULL
10	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
by	NULL
electrophoresis	NULL
in	NULL
denaturing	NULL
condi-	NULL
1613	NULL
Roles	NULL
of	NULL
NF-xB	NULL
activation	NULL
in	NULL
EBV-infected	NULL
B-lymphocytes	NULL
M	NULL
Asso-Bonnet	NULL
et	NULL
al	NULL
1614	NULL
tions	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Ferreira	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
after	NULL
electrotransfer	NULL
onto	NULL
a	NULL
polyvinylidene	NULL
difluoride	NULL
membrane	NULL
(	NULL
Millipore	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
,	NULL
USA	NULL
)	NULL
,	NULL
and	NULL
membrane	NULL
saturation	NULL
with	NULL
gelatine	NULL
,	NULL
incubation	NULL
was	NULL
done	NULL
with	NULL
the	NULL
mouse	NULL
monoclonal	NULL
antibody	NULL
MAD	NULL
10B	NULL
(	NULL
Jaffray	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
,	NULL
a	NULL
generous	NULL
gift	NULL
of	NULL
R	NULL
Hay	NULL
(	NULL
University	NULL
of	NULL
St	NULL
Andrews	NULL
,	NULL
St	NULL
Andrews	NULL
,	NULL
UK	NULL
)	NULL
diluted	NULL
at	NULL
1/400	NULL
.	NULL

Revelation	NULL
of	NULL
the	NULL
antigen/	NULL
antibody	NULL
complex	NULL
was	NULL
performed	NULL
using	NULL
a	NULL
horseradish	NULL
peroxidase-coupled	NULL
anti-mouse	NULL
antibody	NULL
(	NULL
Biorad	NULL
,	NULL
Ivry/	NULL
Seine	NULL
,	NULL
France	NULL
)	NULL
,	NULL
followed	NULL
by	NULL
chemiluminescent	NULL
visualization	NULL
(	NULL
ECL	NULL
system	NULL
,	NULL
Amersham	NULL
,	NULL
Buckinghamshire	NULL
,	NULL
UK	NULL
)	NULL
.	NULL

Immunolabelling	NULL
and	NULL
phenotypic	NULL
analysis	NULL
Antibodies	NULL
used	NULL
are	NULL
listed	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
cell	NULL
surface	NULL
molecules	NULL
was	NULL
assessed	NULL
by	NULL
direct	NULL
and	NULL
indirect	NULL
immunofluorescence	NULL
staining	NULL
using	NULL
a	NULL
Coulter	NULL
XL	NULL
flow	NULL
cytometer	NULL
(	NULL
Coulter	NULL
,	NULL
Margency	NULL
,	NULL
France	NULL
)	NULL
as	NULL
previously	NULL
described	NULL
by	NULL
Feuillard	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Intracytoplasmic	NULL
labelling	NULL
of	NULL
cytokines	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
Picker	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cultured	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
Brefeldin	NULL
A	NULL
(	NULL
Sigma	NULL
,	NULL
I'Isle	NULL
d'Abeau	NULL
Chesne	NULL
,	NULL
France	NULL
)	NULL
at	NULL
10	NULL
ug/ml	NULL
for	NULL
4	NULL
h	NULL
at	NULL
37°C	NULL
to	NULL
allow	NULL
intracytoplasmic	NULL
accumulation	NULL
of	NULL
cytokines	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
washed	NULL
twice	NULL
in	NULL
PBS	NULL
and	NULL
fixed	NULL
in	NULL
4	NULL
%	NULL
paraformaldehyde	NULL
15	NULL
min	NULL
at	NULL
4°C	NULL
in	NULL
a	NULL
dark	NULL
room	NULL
under	NULL
continuous	NULL
gentle	NULL
stirring	NULL
.	NULL

After	NULL
washing	NULL
in	NULL
PBS	NULL
,	NULL
cells	NULL
were	NULL
permeabilized	NULL
using	NULL
a	NULL
commercial	NULL
reagent	NULL
containing	NULL
saponin	NULL
(	NULL
Cytoperm	NULL
B	NULL
,	NULL
Diaclone	NULL
,	NULL
Besangon	NULL
France	NULL
)	NULL
.	NULL

Each	NULL
of	NULL
the	NULL
specific	NULL
antibodies	NULL
against	NULL
cytokines	NULL
were	NULL
added	NULL
to	NULL
10°	NULL
cells	NULL
at	NULL
dilution	NULL
indicated	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

Incubation	NULL
was	NULL
performed	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
in	NULL
a	NULL
dark	NULL
room	NULL
under	NULL
continuous	NULL
gentle	NULL
stirring	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
once	NULL
in	NULL
PBS	NULL
with	NULL
0.5	NULL
%	NULL
serum	NULL
bovine	NULL
albumin	NULL
and	NULL
0.2	NULL
%	NULL
saponin	NULL
(	NULL
Sigma	NULL
)	NULL
and	NULL
then	NULL
washed	NULL
once	NULL
in	NULL
PBS	NULL
alone	NULL
.	NULL

Flow	NULL
cytometry	NULL
analysis	NULL
was	NULL
done	NULL
on	NULL
cells	NULL
gated	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
their	NULL
forward	NULL
and	NULL
90°	NULL
light	NULL
scatter	NULL
plot	NULL
and	NULL
negative	NULL
controls	NULL
consisted	NULL
in	NULL
irrelevant	NULL
antibodies	NULL
purchased	NULL
from	NULL
Coulter	NULL
.	NULL

Latency	NULL
of	NULL
EBV	NULL
in	NULL
cells	NULL
was	NULL
assessed	NULL
using	NULL
immunocytochemistry	NULL
by	NULL
analysing	NULL
the	NULL
expression	NULL
of	NULL
EBNA1I	NULL
,	NULL
EBNA2	NULL
and	NULL
LMP1	NULL
molecules	NULL
.	NULL

Fifty	NULL
thousand	NULL
cells	NULL
per	NULL
slide	NULL
were	NULL
cytocentrifuged	NULL
and	NULL
air	NULL
dried	NULL
.	NULL

Cells	NULL
were	NULL
fixed	NULL
in	NULL
4	NULL
%	NULL
paraformaldehyde	NULL
for	NULL
EBNA1	NULL
labelling	NULL
and	NULL
in	NULL
acetone	NULL
for	NULL
EBNA2Z	NULL
and	NULL
LMP1I	NULL
.	NULL

An	NULL
indirect	NULL
three	NULL
stage	NULL
immunoper-oxidase	NULL
technique	NULL
using	NULL
the	NULL
Vectastain	NULL
kit	NULL
(	NULL
Burlingame	NULL
,	NULL
CA	NULL
,	NULL
USA	NULL
)	NULL
was	NULL
performed	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
procedure	NULL
.	NULL

The	NULL
biotinylated	NULL
anti-mouse	NULL
and	NULL
anti-rat	NULL
im-mune-serum	NULL
were	NULL
obtained	NULL
from	NULL
Vectastain	NULL
and	NULL
were	NULL
used	NULL
diluted	NULL
at	NULL
1/150	NULL
.	NULL

The	NULL
avidin	NULL
peroxidase	NULL
complex	NULL
was	NULL
used	NULL
diluted	NULL
at	NULL
1/125	NULL
.	NULL

Peroxidase	NULL
reaction	NULL
,	NULL
which	NULL
generates	NULL
a	NULL
brown	NULL
labelling	NULL
,	NULL
was	NULL
performed	NULL
using	NULL
di-amino-benzidine	NULL
tablets	NULL
(	NULL
Sigma	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

Counterstaining	NULL
was	NULL
done	NULL
with	NULL
Harris	NULL
Haematoxilin	NULL
that	NULL
stains	NULL
nuclei	NULL
in	NULL
blue	NULL
.	NULL

Control	NULL
performed	NULL
in	NULL
parallel	NULL
consisted	NULL
of	NULL
irrelevant	NULL
mouse	NULL
or	NULL
rat	NULL
monoclonal	NULL
antibody	NULL
.	NULL

Cell	NULL
cycle	NULL
analysis	NULL
and	NULL
apoptosis	NULL
detection	NULL
Analysis	NULL
of	NULL
cell	NULL
cycle	NULL
and	NULL
detection	NULL
of	NULL
apoptosis	NULL
was	NULL
done	NULL
after	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
TNFa	NULL
(	NULL
Sigma	NULL
)	NULL
at	NULL
10	NULL
ng/ml	NULL
.	NULL

The	NULL
cell	NULL
cycle	NULL
was	NULL
analysed	NULL
by	NULL
flow	NULL
cytometry	NULL
after	NULL
bromodeoxyuridine	NULL
(	NULL
BrdU	NULL
)	NULL
incorporation	NULL
and	NULL
staining	NULL
of	NULL
DNA	NULL
with	NULL
propidium	NULL
iodide	NULL
as	NULL
described	NULL
(	NULL
Lowe	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
4	NULL
h	NULL
with	NULL
BrdU	NULL
(	NULL
Sigma	NULL
)	NULL
at	NULL
10	NULL
uM	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
and	NULL
fixed	NULL
in	NULL
ethanol	NULL
,	NULL
resuspended	NULL
in	NULL
2	NULL
N	NULL
HCl	NULL
solution	NULL
with	NULL
0.2	NULL
mg/ml	NULL
pepsin	NULL
for	NULL
30	NULL
min	NULL
.	NULL

Neutralization	NULL
was	NULL
done	NULL
with	NULL
0.1	NULL
M	NULL
sodium	NULL
borate	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
in	NULL
PBS	NULL
and	NULL
resuspended	NULL
in	NULL
PBS	NULL
plus	NULL
2	NULL
%	NULL
foetal	NULL
calf	NULL
serum	NULL
and	NULL
0.5	NULL
%	NULL
Tween	NULL
20	NULL
(	NULL
PTS	NULL
)	NULL
.	NULL

BrdU	NULL
incorporated	NULL
in	NULL
DNA	NULL
was	NULL
labelled	NULL
with	NULL
a	NULL
FITC-conjugated	NULL
antiBrdU	NULL
antibody	NULL
(	NULL
Boehringer	NULL
,	NULL
Meylan	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
in	NULL
PTS	NULL
and	NULL
resuspended	NULL
in	NULL
PTS	NULL
containing	NULL
0.5	NULL
mg/ml	NULL
RNAse	NULL
A	NULL
(	NULL
Quiagen	NULL
,	NULL
Courtaboeuf	NULL
,	NULL
France	NULL
)	NULL
and	NULL
Table	NULL
1	NULL
List	NULL
of	NULL
antibodies	NULL
used	NULL
Specificity	NULL
Clone	NULL
Dilution	NULL
Supplier	NULL
Fluoro-chrome	NULL
CD3	NULL
X35	NULL
1/20	NULL
Immunotech	NULL
'	NULL
none	NULL
CDS	NULL
DK23	NULL
1/20	NULL
Dako	NULL
``	NULL
FITC	NULL
(	NULL
a	NULL
)	NULL
CD10	NULL
J5	NULL
1/20	NULL
Coulter	NULL
!	NULL

FITC	NULL
CDla	NULL
25.3	NULL
1/20	NULL
Immunotech	NULL
none	NULL
CD18	NULL
BLS	NULL
1/30	NULL
Immunotech	NULL
none	NULL
CD19	NULL
B4:89D	NULL
1/25	NULL
Coulter	NULL
PE	NULL
(	NULL
b	NULL
)	NULL
CD20	NULL
Bly.1	NULL
1/20	NULL
Dako	NULL
FITC	NULL
CD21	NULL
B120	NULL
1/20	NULL
Coulter	NULL
PF	NULL
CD23	NULL
MHM6	NULL
1/20	NULL
Dako	NULL
FITC	NULL
CD25	NULL
1	NULL
HT44H3	NULL
1/20	NULL
Coulter	NULL
FITC	NULL
CD30	NULL
HRS4	NULL
1/30	NULL
Immunotech	NULL
none	NULL
CD38	NULL
T16	NULL
1/30	NULL
Becton-Dickinson	NULL
PE	NULL
CD39	NULL
AC2	NULL
1/20	NULL
Immunotech	NULL
none	NULL
CD44	NULL
J173	NULL
1/20	NULL
Immunotech	NULL
none	NULL
CD48	NULL
14.57	NULL
1/30	NULL
Immunotech	NULL
none	NULL
CD34	NULL
84H10	NULL
1/10	NULL
Immunotech	NULL
FITC	NULL
CD58	NULL
AICD38	NULL
1/30	NULL
Immunotech	NULL
none	NULL
CD71	NULL
37L	NULL
1/20	NULL
Coulter	NULL
FITC	NULL
CD80	NULL
MAB1.4	NULL
1/20	NULL
Immunotech	NULL
none	NULL
CD95	NULL
CH-11	NULL
1/5	NULL
Immunotech	NULL
none	NULL
IgG	NULL
8a4	NULL
1/20	NULL
Dako	NULL
FITC	NULL
IgA	NULL
NIF2	NULL
1/20	NULL
Dako	NULL
FITC	NULL
IgM	NULL
AF6	NULL
1/20	NULL
Dako	NULL
FITC	NULL
IgD	NULL
JAll	NULL
1/20	NULL
Dako	NULL
FITC	NULL
kappa	NULL
6E1	NULL
1/20	NULL
Dako	NULL
FITC	NULL
lambda	NULL
C4	NULL
1/20	NULL
Dako	NULL
FITC	NULL
HLA	NULL
I	NULL
B9.12.1	NULL
1/50	NULL
Immunotech	NULL
none	NULL
HLA	NULL
II	NULL
B8.12.2	NULL
1/50	NULL
Immunotech	NULL
none	NULL
F	NULL
(	NULL
ab	NULL
)	NULL
polyclonal	NULL
1/20	NULL
Dako	NULL
FITC	NULL
LMP1	NULL
CS1-4	NULL
1/20	NULL
Dako	NULL
none	NULL
EBNA1	NULL
2B4	NULL
1/20	NULL
E.Krammer*	NULL
none	NULL
EBNA2	NULL
PE2	NULL
1/20	NULL
Dako	NULL
none	NULL
ZEBRA	NULL
BZ.1	NULL
1/20	NULL
Dako	NULL
none	NULL
IL2	NULL
B-GSIL2	NULL
1/20	NULL
Diaclone*	NULL
FITC	NULL
IL6	NULL
B-E8IL6	NULL
1/20	NULL
Diaclone	NULL
FITC	NULL
IL10	NULL
B6TIOIL10	NULL
1/20	NULL
Diaclone	NULL
FITC	NULL
TNFa	NULL
B-DITNFa	NULL
1/20	NULL
Diaclone	NULL
FITC	NULL
(	NULL
a	NULL
)	NULL
FITC	NULL
:	NULL
Fluorescein	NULL
isothiocyanate	NULL
;	NULL
(	NULL
b	NULL
)	NULL
PE	NULL
:	NULL
PhycoErythrine	NULL
.	NULL

*Institut	NULL
fiir	NULL
Immunologie	NULL
,	NULL
Haematologikum	NULL
,	NULL
GSF	NULL
,	NULL
Munich	NULL
,	NULL
Germany	NULL
.	NULL

1	NULL
:	NULL
Coulter-Immunotech	NULL
:	NULL
Margency	NULL
,	NULL
France	NULL
.	NULL

2	NULL
;	NULL
Dako	NULL
,	NULL
Trappes	NULL
,	NULL
France	NULL
.	NULL

3	NULL
:	NULL
Becton-Dickinson	NULL
,	NULL
Erembodegem-Aalst	NULL
,	NULL
Bel-gium	NULL
.	NULL

4	NULL
;	NULL
Diaclone	NULL
,	NULL
Besangon	NULL
,	NULL
France	NULL
50	NULL
ug/ml	NULL
of	NULL
propidium	NULL
iodide	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

To	NULL
eliminate	NULL
cell	NULL
aggregates	NULL
from	NULL
the	NULL
analysis	NULL
,	NULL
flow	NULL
cytometry	NULL
analysis	NULL
was	NULL
done	NULL
on	NULL
cells	NULL
gated	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
both	NULL
their	NULL
forward	NULL
and	NULL
90°	NULL
light	NULL
scatter	NULL
plot	NULL
and	NULL
the	NULL
peak	NULL
and	NULL
the	NULL
mean	NULL
of	NULL
the	NULL
propidium	NULL
iodide	NULL
fluorescence	NULL
scatter	NULL
plot	NULL
.	NULL

For	NULL
apoptosis	NULL
detection	NULL
,	NULL
50	NULL
000	NULL
cells	NULL
were	NULL
cytocentrifuged	NULL
on	NULL
slides	NULL
.	NULL

Apoptosis	NULL
of	NULL
cells	NULL
was	NULL
first	NULL
recognized	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
cell	NULL
morphology	NULL
after	NULL
May	NULL
Griinwald	NULL
Giemsa	NULL
staining	NULL
.	NULL

Apoptosis	NULL
was	NULL
confirmed	NULL
by	NULL
detection	NULL
of	NULL
DNA	NULL
strand	NULL
breaks	NULL
using	NULL
the	NULL
TUNEL	NULL
method	NULL
,	NULL
according	NULL
to	NULL
the	NULL
instructions	NULL
of	NULL
the	NULL
manufacturer	NULL
(	NULL
Boehringer	NULL
)	NULL
.	NULL

Percentage	NULL
of	NULL
apoptotic	NULL
cells	NULL
was	NULL
estimated	NULL
under	NULL
fluorescence	NULL
microscope	NULL
by	NULL
counting	NULL
cells	NULL
having	NULL
DNA	NULL
strand	NULL
breaks	NULL
.	NULL

Acknowledgements	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
ANRS	NULL
,	NULL
Paris	NULL
,	NULL
France	NULL
,	NULL
contrat	NULL
No	NULL
96003	NULL
et	NULL
98017	NULL
.	NULL

We	NULL
would	NULL
like	NULL
to	NULL
thank	NULL
Pr	NULL
G	NULL
Lenoir	NULL
(	NULL
CIRC	NULL
,	NULL
Lyon	NULL
,	NULL
France	NULL
)	NULL
and	NULL
F	NULL
Praz	NULL
(	NULL
IGR	NULL
,	NULL
Villejuif	NULL
,	NULL
France	NULL
)	NULL
for	NULL
the	NULL
kind	NULL
gift	NULL
of	NULL
cell	NULL
lines	NULL
.	NULL

We	NULL
thank	NULL
Dr	NULL
N	NULL
Rice	NULL
(	NULL
NCI	NULL
,	NULL
Frederick	NULL
,	NULL
USA	NULL
)	NULL
for	NULL
the	NULL
generous	NULL
gift	NULL
of	NULL
immune	NULL
serum	NULL
against	NULL
Rel/NF-xB	NULL
proteins	NULL
and	NULL
R	NULL
Hay	NULL
(	NULL
University	NULL
of	NULL
St	NULL
Andrews	NULL
,	NULL
St	NULL
Andrews	NULL
,	NULL
UK	NULL
)	NULL
for	NULL
the	NULL
generous	NULL
gift	NULL
of	NULL
the	NULL
MAD	NULL
10B	NULL
monoclonal	NULL
antibody	NULL
.	NULL

We	NULL
thank	NULL
Dr	NULL
E	NULL
Krammer	NULL
(	NULL
Institut	NULL
fiir	NULL
Immunologie	NULL
,	NULL
Haematologikum	NULL
,	NULL
GSF	NULL
,	NULL
Munich	NULL
,	NULL
Germany	NULL
)	NULL
for	NULL
the	NULL
kind	NULL
gift	NULL
of	NULL
the	NULL
2B4	NULL
antibody	NULL
.	NULL

References	NULL
Arenzana-Seisdedos	NULL
F	NULL
,	NULL
Thompson	NULL
J	NULL
,	NULL
Rodriguez	NULL
MS	NULL
,	NULL
Bachelerie	NULL
F	NULL
,	NULL
Thomas	NULL
D	NULL
and	NULL
Hay	NULL
RT	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
15	NULL
,	NULL
2689-2696	NULL
.	NULL

Bacuerle	NULL
PA	NULL
and	NULL
Baltimore	NULL
D.	NULL
(	NULL
1989	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
3	NULL
,	NULL
1689	NULL
1698	NULL
.	NULL

Baecuerle	NULL
PA	NULL
and	NULL
Henkel	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

Ann	NULL
.	NULL

,	NULL
Rev	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
12	NULL
,	NULL
141-179	NULL
.	NULL

Beg	NULL
AA	NULL
and	NULL
Baltimore	NULL
D.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
274	NULL
,	NULL
782-784	NULL
.	NULL

Carrasco	NULL
D	NULL
,	NULL
Rizzo	NULL
CA	NULL
,	NULL
Dorfman	NULL
K	NULL
and	NULL
Bravo	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
15	NULL
,	NULL
3640-3650	NULL
.	NULL

Collart	NULL
MA	NULL
,	NULL
Baeuerle	NULL
P	NULL
and	NULL
Vassalli	NULL
P.	NULL
(	NULL
1990	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
10	NULL
,	NULL
1498-1506	NULL
.	NULL

Coral	NULL
S	NULL
,	NULL
Pucillo	NULL
C	NULL
,	NULL
Leonardi	NULL
A	NULL
,	NULL
Fonsatti	NULL
E	NULL
,	NULL
Altomonte	NULL
M	NULL
and	NULL
Maio	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

Cell	NULL
Growth	NULL
Differ	NULL
.	NULL

,	NULL
8	NULL
,	NULL
581-588	NULL
.	NULL

Cordingley	NULL
FT	NULL
,	NULL
Bianchi	NULL
A	NULL
,	NULL
Hoffbrand	NULL
AV	NULL
,	NULL
Reittie	NULL
JE	NULL
,	NULL
Heslop	NULL
HE	NULL
,	NULL
Vyakarnam	NULL
A	NULL
,	NULL
Turner	NULL
M	NULL
,	NULL
Meager	NULL
A	NULL
and	NULL
Brenner	NULL
MK	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
.	NULL

Lancet	NULL
,	NULL
1	NULL
,	NULL
969-971	NULL
.	NULL

Cressman	NULL
DE	NULL
and	NULL
Taub	NULL
R.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
8	NULL
,	NULL
2567-2573	NULL
.	NULL

Ferreira	NULL
V	NULL
,	NULL
Tarantino	NULL
N	NULL
and	NULL
Korner	NULL
M.	NULL
(	NULL
1998	NULL
)	NULL
.	NULL

J.	NULL
Bio	NULL
!	NULL

.	NULL

Chem	NULL
.	NULL

,	NULL
273	NULL
,	NULL
592-599	NULL
.	NULL

Feuillard	NULL
J	NULL
,	NULL
Gouy	NULL
H	NULL
,	NULL
Bismuth	NULL
G	NULL
,	NULL
Lee	NULL
LM	NULL
,	NULL
Debre	NULL
P	NULL
and	NULL
Korner	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

Cytokine	NULL
,	NULL
3	NULL
,	NULL
257-265	NULL
.	NULL

Feuillard	NULL
J	NULL
,	NULL
Taylor	NULL
D	NULL
,	NULL
Casamayor-Palleja	NULL
M	NULL
,	NULL
Johnson	NULL
GD	NULL
and	NULL
MacLennan	NULL
IC	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
7	NULL
,	NULL
121-130	NULL
.	NULL

Goldfeld	NULL
AE	NULL
,	NULL
Doyle	NULL
C	NULL
and	NULL
Maniatis	NULL
T.	NULL
(	NULL
1990	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Nat	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
87	NULL
,	NULL
9769-9773	NULL
.	NULL

Goldfeld	NULL
AE	NULL
,	NULL
Strominger	NULL
JL	NULL
and	NULL
Doyle	NULL
C.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
,	NULL
174	NULL
,	NULL
73-81	NULL
.	NULL

Grilli	NULL
M	NULL
,	NULL
Chiu	NULL
JJ	NULL
and	NULL
Lenardo	NULL
MJ	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Internat	NULL
.	NULL

Rev	NULL
.	NULL

Cytol	NULL
.	NULL

,	NULL
143	NULL
,	NULL
1-62	NULL
.	NULL

Grossman	NULL
SR	NULL
,	NULL
Johannsen	NULL
E	NULL
,	NULL
Tong	NULL
X	NULL
,	NULL
Yalamanchili	NULL
R	NULL
and	NULL
Kieff	NULL
E.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Nat	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
91	NULL
,	NULL
7568	NULL
7572	NULL
.	NULL

Henkel	NULL
T	NULL
,	NULL
Ling	NULL
]	NULL
PD	NULL
,	NULL
Hayward	NULL
SD	NULL
and	NULL
Peterson	NULL
MG.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
265	NULL
,	NULL
92-95	NULL
.	NULL

Herrero	NULL
JA	NULL
,	NULL
Mathew	NULL
P	NULL
and	NULL
Paya	NULL
CV	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
69	NULL
,	NULL
2168-2174	NULL
.	NULL

Higgins	NULL
KA	NULL
,	NULL
Perez	NULL
JR	NULL
,	NULL
Coleman	NULL
TA	NULL
,	NULL
Dorshkind	NULL
K	NULL
,	NULL
McComas	NULL
WA	NULL
,	NULL
Sarmiento	NULL
UM	NULL
,	NULL
Rosen	NULL
CA	NULL
and	NULL
Naraya-nan	NULL
R.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
90	NULL
,	NULL
9901-9905	NULL
.	NULL

Houldsworth	NULL
J	NULL
,	NULL
Mathew	NULL
S	NULL
,	NULL
Rao	NULL
PH	NULL
,	NULL
Dyomina	NULL
K	NULL
,	NULL
Louie	NULL
DC	NULL
,	NULL
Parsa	NULL
N	NULL
,	NULL
Offit	NULL
K	NULL
and	NULL
Chaganti	NULL
RSK	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
87	NULL
,	NULL
25	NULL
.	NULL

Hsieh	NULL
JJ	NULL
and	NULL
Hayward	NULL
SD	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
268	NULL
,	NULL
560-563	NULL
.	NULL

Huen	NULL
DS	NULL
,	NULL
Henderson	NULL
SA	NULL
,	NULL
Croom-Carter	NULL
D	NULL
and	NULL
Rowe	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
10	NULL
,	NULL
549-560	NULL
.	NULL

Jaffray	NULL
E	NULL
,	NULL
Wood	NULL
KM	NULL
and	NULL
Hay	NULL
RT	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
15	NULL
,	NULL
2166-2172	NULL
.	NULL

Jelinek	NULL
DF	NULL
and	NULL
Lipsky	NULL
PE	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
!	NULL

.	NULL

,	NULL
139	NULL
,	NULL
2970	NULL
2976	NULL
.	NULL

Jochems	NULL
GJ	NULL
,	NULL
Klein	NULL
MR	NULL
,	NULL
Jordens	NULL
R	NULL
,	NULL
Pascual-Salcedo	NULL
D	NULL
,	NULL
van	NULL
Boxtel-Oosterhof	NULL
F	NULL
,	NULL
van	NULL
Lier	NULL
RA	NULL
and	NULL
Zeijlemaker	NULL
WP	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

Hum	NULL
.	NULL

Antibodies	NULL
Hybridomas	NULL
,	NULL
2	NULL
,	NULL
57-64	NULL
.	NULL

Kaye	NULL
KM	NULL
,	NULL
Devergne	NULL
O	NULL
,	NULL
Harada	NULL
JN	NULL
,	NULL
Izumi	NULL
KM	NULL
,	NULL
Yalamanchili	NULL
R	NULL
,	NULL
Kieff	NULL
E	NULL
and	NULL
Mosialos	NULL
G.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Nat/	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
93	NULL
,	NULL
11085-11090	NULL
.	NULL

Kehrl	NULL
JH	NULL
,	NULL
Miller	NULL
A	NULL
and	NULL
Fauci	NULL
AS	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
166	NULL
,	NULL
786-791	NULL
.	NULL

Kieff	NULL
E	NULL
and	NULL
Liebowtz	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
and	NULL
its	NULL
replication	NULL
,	NULL
2	NULL
edn	NULL
.	NULL

Raven	NULL
Press	NULL
,	NULL
New	NULL
York	NULL
.	NULL

Klein	NULL
SC	NULL
,	NULL
Kube	NULL
D	NULL
,	NULL
Abts	NULL
H	NULL
,	NULL
Diehl	NULL
V	NULL
and	NULL
Tesch	NULL
H.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Leuk	NULL
.	NULL

Res	NULL
.	NULL

,	NULL
20	NULL
,	NULL
633-663	NULL
.	NULL

Korner	NULL
M	NULL
,	NULL
Bellan	NULL
AH	NULL
,	NULL
Brini	NULL
AT	NULL
and	NULL
Farrar	NULL
WL	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

Biochem	NULL
.	NULL

J.	NULL
,	NULL
265	NULL
,	NULL
547-554	NULL
.	NULL

Laherty	NULL
CD	NULL
,	NULL
Hu	NULL
HM	NULL
,	NULL
Opipari	NULL
AW	NULL
,	NULL
Wang	NULL
F	NULL
and	NULL
Dixit	NULL
VM	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
267	NULL
,	NULL
24157-24160	NULL
.	NULL

Libermann	NULL
TA	NULL
and	NULL
Baltimore	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
10	NULL
,	NULL
2327-2334	NULL
.	NULL

Liou	NULL
HC	NULL
,	NULL
Nolan	NULL
GP	NULL
,	NULL
Ghosh	NULL
S	NULL
,	NULL
Fujita	NULL
T	NULL
and	NULL
Baltimore	NULL
D.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
11	NULL
,	NULL
3003-3009	NULL
.	NULL

Lowe	NULL
SW	NULL
,	NULL
Ruley	NULL
HE	NULL
,	NULL
Jacks	NULL
T	NULL
and	NULL
Housman	NULL
DE	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
74	NULL
,	NULL
957-967	NULL
.	NULL

Roles	NULL
of	NULL
NF-xB	NULL
activation	NULL
in	NULL
EBV-infected	NULL
B-lymphocytes	NULL
M	NULL
Asso-Bonnet	NULL
et	NULL
al	NULL
Macia	NULL
J	NULL
,	NULL
Gomez	NULL
X	NULL
,	NULL
Esquerda	NULL
A	NULL
,	NULL
Perez	NULL
B	NULL
,	NULL
Callao	NULL
V	NULL
and	NULL
Marzo	NULL
C.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Leuk	NULL
Lymphoma	NULL
,	NULL
20	NULL
,	NULL
481-486	NULL
.	NULL

McGuire	NULL
W	NULL
,	NULL
Hill	NULL
AV	NULL
,	NULL
Allsopp	NULL
CE	NULL
,	NULL
Greenwood	NULL
BM	NULL
and	NULL
Kwiatkowski	NULL
D.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
371	NULL
,	NULL
508-510	NULL
.	NULL

Migliazza	NULL
A	NULL
,	NULL
Lombardi	NULL
L	NULL
,	NULL
Rocchi	NULL
M	NULL
,	NULL
Trecca	NULL
D	NULL
,	NULL
Chang	NULL
CC	NULL
,	NULL
Antonacei	NULL
R	NULL
,	NULL
Fracchiolla	NULL
NS	NULL
,	NULL
Ciana	NULL
P	NULL
,	NULL
Maiolo	NULL
AT	NULL
and	NULL
Neri	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
84	NULL
,	NULL
3850-3860	NULL
.	NULL

Mosialos	NULL
G	NULL
,	NULL
Birkenbach	NULL
M	NULL
,	NULL
Yalamanchili	NULL
R	NULL
,	NULL
VanArsdale	NULL
T	NULL
,	NULL
Ware	NULL
C	NULL
and	NULL
Kieff	NULL
E.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
80	NULL
,	NULL
389-399	NULL
.	NULL

Nakshatri	NULL
H	NULL
,	NULL
Bhat-Nakshatri	NULL
P	NULL
,	NULL
Martin	NULL
DA	NULL
,	NULL
Goulet	NULL
Jr	NULL
RJ	NULL
,	NULL
and	NULL
Sledge	NULL
Jr	NULL
GW	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
17	NULL
,	NULL
3629-3639	NULL
.	NULL

Neri	NULL
A	NULL
,	NULL
Chang	NULL
CC	NULL
,	NULL
Lombardi	NULL
L	NULL
,	NULL
Salina	NULL
M	NULL
,	NULL
Corradini	NULL
P	NULL
,	NULL
Maiolo	NULL
AT	NULL
,	NULL
Chaganti	NULL
RS	NULL
and	NULL
Dalla-Favera	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
67	NULL
,	NULL
1075-1087	NULL
.	NULL

Osnes	NULL
LT	NULL
,	NULL
Foss	NULL
KB	NULL
,	NULL
Joo	NULL
GB	NULL
,	NULL
Okkenhaug	NULL
C	NULL
,	NULL
Westvik	NULL
AB	NULL
,	NULL
Ovstebo	NULL
R	NULL
and	NULL
Kierulf	NULL
P.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Thromb	NULL
.	NULL

Haemost	NULL
.	NULL

,	NULL
76	NULL
,	NULL
970-976	NULL
.	NULL

Picker	NULL
LJ	NULL
,	NULL
Singh	NULL
MK	NULL
,	NULL
Zdraveski	NULL
Z	NULL
,	NULL
Treer	NULL
JR	NULL
,	NULL
Waldrop	NULL
SL	NULL
,	NULL
Bergstresser	NULL
PR	NULL
and	NULL
Maino	NULL
VC	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
86	NULL
,	NULL
1408	NULL
1419	NULL
.	NULL

Plaisance	NULL
S	NULL
,	NULL
Vanden	NULL
Berghe	NULL
W	NULL
,	NULL
Boone	NULL
E	NULL
,	NULL
Fiers	NULL
W	NULL
and	NULL
Haegeman	NULL
G.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
17	NULL
,	NULL
3733-3743	NULL
.	NULL

Rothenberger	NULL
S	NULL
,	NULL
Bachmann	NULL
E	NULL
,	NULL
Berger	NULL
C	NULL
,	NULL
McQuain	NULL
C	NULL
,	NULL
Odermatt	NULL
BF	NULL
and	NULL
Knecht	NULL
H.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
14	NULL
,	NULL
2123-2126	NULL
.	NULL

Salles	NULL
G	NULL
,	NULL
Bienvenu	NULL
J	NULL
,	NULL
Bastion	NULL
Y	NULL
,	NULL
Barbier	NULL
Y	NULL
,	NULL
Doche	NULL
C	NULL
,	NULL
Warzocha	NULL
K	NULL
,	NULL
Gutowski	NULL
MC	NULL
,	NULL
Rieux	NULL
C	NULL
and	NULL
Coiffier	NULL
B	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Haematol	NULL
.	NULL

,	NULL
93	NULL
,	NULL
352-359	NULL
.	NULL

Shackelford	NULL
RE	NULL
,	NULL
Alford	NULL
PB	NULL
,	NULL
Xue	NULL
Y	NULL
,	NULL
Thai	NULL
SF	NULL
,	NULL
Adams	NULL
DO	NULL
and	NULL
Pizzo	NULL
S.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Pharmacol	NULL
.	NULL

,	NULL
52	NULL
,	NULL
421-429	NULL
.	NULL

Shakhov	NULL
AN	NULL
,	NULL
Collart	NULL
MA	NULL
,	NULL
Vassalli	NULL
P	NULL
,	NULL
Nedospasov	NULL
SA	NULL
and	NULL
Jongeneel	NULL
CV	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
171	NULL
,	NULL
35-47	NULL
.	NULL

Simek	NULL
SL	NULL
,	NULL
Stephens	NULL
RM	NULL
and	NULL
Rice	NULL
NR	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
59	NULL
,	NULL
120-126	NULL
.	NULL

Sovak	NULL
MA	NULL
,	NULL
Bellas	NULL
RE	NULL
,	NULL
Kim	NULL
DW	NULL
,	NULL
Zanieski	NULL
GJ	NULL
,	NULL
Rogers	NULL
AE	NULL
,	NULL
Traish	NULL
AM	NULL
and	NULL
Sonenshein	NULL
GE	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

J.	NULL
C/in	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
100	NULL
,	NULL
2952-2960	NULL
.	NULL

Stephens	NULL
RM	NULL
,	NULL
Rice	NULL
NR	NULL
,	NULL
Hiebsch	NULL
RR	NULL
,	NULL
Bose	NULL
Jr	NULL
HR	NULL
and	NULL
Gilden	NULL
RV	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
80	NULL
,	NULL
6229	NULL
6233	NULL
.	NULL

Sugano	NULL
N	NULL
,	NULL
Chen	NULL
W	NULL
,	NULL
Roberts	NULL
ML	NULL
and	NULL
Cooper	NULL
NR	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
186	NULL
,	NULL
731-737	NULL
.	NULL

Sung	NULL
SS	NULL
,	NULL
Jung	NULL
LK	NULL
,	NULL
Walters	NULL
JA	NULL
,	NULL
Chen	NULL
W	NULL
,	NULL
Wang	NULL
CY	NULL
and	NULL
Fu	NULL
SM	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
168	NULL
,	NULL
1539-1551	NULL
.	NULL

Ten	NULL
RM	NULL
,	NULL
Paya	NULL
CV	NULL
,	NULL
Israel	NULL
N	NULL
,	NULL
Le	NULL
Bail	NULL
O	NULL
,	NULL
Mattei	NULL
MG	NULL
,	NULL
Virelizier	NULL
JL	NULL
,	NULL
Kourilsky	NULL
P	NULL
and	NULL
Israel	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
11	NULL
,	NULL
195-203	NULL
.	NULL

Traenckner	NULL
EB	NULL
,	NULL
Pahl	NULL
HL	NULL
,	NULL
Henkel	NULL
T	NULL
,	NULL
Schmidt	NULL
KN	NULL
,	NULL
Wilk	NULL
S	NULL
and	NULL
Bacuerle	NULL
PA.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
14	NULL
,	NULL
2876-2883	NULL
.	NULL

Van	NULL
Antwerp	NULL
DJ	NULL
,	NULL
Martin	NULL
SJ	NULL
,	NULL
Kafri	NULL
T	NULL
,	NULL
Green	NULL
DR	NULL
and	NULL
Verma	NULL
IM	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
274	NULL
,	NULL
787-789	NULL
.	NULL

Verma	NULL
IM	NULL
,	NULL
Stevenson	NULL
JK	NULL
,	NULL
Schwarz	NULL
EM	NULL
,	NULL
Van	NULL
Antwerp	NULL
D	NULL
and	NULL
Miyamoto	NULL
S.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
9	NULL
,	NULL
2723-2735	NULL
.	NULL

Waltzer	NULL
L	NULL
,	NULL
Bourillot	NULL
PY	NULL
,	NULL
Sergeant	NULL
A	NULL
and	NULL
Manet	NULL
E.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
23	NULL
,	NULL
4939-4945	NULL
.	NULL

Wang	NULL
CY	NULL
,	NULL
Mayo	NULL
MW	NULL
and	NULL
Baldwin	NULL
Jr	NULL
AS	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
274	NULL
,	NULL
784-787	NULL
.	NULL

Warzocha	NULL
K	NULL
,	NULL
Salles	NULL
G	NULL
,	NULL
Bienvenu	NULL
J	NULL
,	NULL
Barbier	NULL
Y	NULL
,	NULL
Bastion	NULL
Y	NULL
,	NULL
Doche	NULL
C	NULL
,	NULL
Rieux	NULL
C	NULL
and	NULL
Coiffier	NULL
B	NULL
.	NULL

(	NULL
1997a	NULL
)	NULL
.	NULL

Leukemia	NULL
,	NULL
11	NULL
,	NULL
441-443	NULL
.	NULL

Warzocha	NULL
K	NULL
,	NULL
Salles	NULL
G	NULL
,	NULL
Bienvenu	NULL
J	NULL
,	NULL
Bastion	NULL
Y	NULL
,	NULL
Dumontet	NULL
C	NULL
,	NULL
Renard	NULL
N	NULL
,	NULL
Neidhardt-Berard	NULL
EM	NULL
and	NULL
Coiffier	NULL
B	NULL
.	NULL

(	NULL
1997b	NULL
)	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Oncol	NULL
.	NULL

,	NULL
15	NULL
,	NULL
499-508	NULL
.	NULL

Wu	NULL
F	NULL
,	NULL
Garcia	NULL
J	NULL
,	NULL
Mitsuyasu	NULL
R	NULL
and	NULL
Gaynor	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
62	NULL
,	NULL
218-225	NULL
.	NULL

Zabel	NULL
U	NULL
,	NULL
Henkel	NULL
T	NULL
,	NULL
Silva	NULL
MS	NULL
and	NULL
Baeuerle	NULL
PA.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
12	NULL
,	NULL
201-211	NULL
.	NULL

Zimber-Strobl	NULL
U	NULL
,	NULL
Strobl	NULL
LJ	NULL
,	NULL
Meitinger	NULL
C	NULL
,	NULL
Hinrichs	NULL
R	NULL
,	NULL
Sakai	NULL
T	NULL
,	NULL
Furukawa	NULL
T	NULL
,	NULL
Honjo	NULL
J	NULL
and	NULL
Bornkamm	NULL
GW	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
13	NULL
,	NULL
4973-4982	NULL
.	NULL

1615	NULL

